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ABSTRACT 
The intestinal mucosa represents one of the largest barrier sites of our body, having to 
withstand a constant exposure to a plethora of environmental insults (including dietary 
compounds, xenobiotics, metabolites and microorganisms). While our body has evolved 
tolerance/ignorance towards some of these factors deemed beneficial for the host, it requires 
constant maintenance of epithelial barrier integrity and ability to mount pro-inflammatory 
responses to protect against potentially harmful environmental insults. The intestinal 
epithelium and innate lymphoid cells (ILCs) are two fundamental players in safeguarding 
intestinal homeostasis. The goal of this thesis was to study how ILC development/functions 
and the regenerative capacity of the intestinal epithelium are shaped by the intestinal 
inflammatory and metabolic milieu.  
In study I, we investigated whether the pool of adult ILC progenitors in the bone marrow 
was able to sense and respond to peripheral inflammation. We found that increase in systemic 
levels of the cytokine Flt3L resulted in expansion of ILC precursors committed to helper 
ILCs. Although ILCs expand in inflammatory bowel disease patients, this axis does not take 
place in response to intestinal inflammation. However, in the context of malaria, increased 
levels of systemic Flt3L correlated with expansion of bone marrow ILC precursors, thus 
suggesting a potential role for inflammatory ILC lymphopoiesis during malaria.  
In study II, we explored how alteration in cholesterol metabolism affected the function of 
intestinal ILCs. We showed that ILC3s, through the receptor EBI2, sensed cholesterol 
metabolites (oxysterols) produced by colonic stromal cells. Activation of this pathway led to 
ILC3 migration and thus formation of colonic lymphoid tissues (cryptopatches and isolated 
lymphoid follicles). Migration of ILC3s to cryptopatches resulted in their acquired ability to 
produce interleukin (IL)-22, a key intestinal homeostatic cytokine. However, in the context of 
colitis, augmented oxysterol production promoted EBI2-mediated inflammation and tissue 
remodeling. 
In study III, we further investigated the contribution of cholesterol metabolism in intestinal 
physiology and found that a distinct oxysterol receptor (LXR) controlled the regenerative 
response of the intestinal epithelium. In the context of intestinal damage, oxysterol 
production and LXR activation was enhanced. Boosting activation of this pathway in 
intestinal epithelial cells enhanced regeneration in response to injury by promoting the 
activity of intestinal stem cells. Remarkably, in the context of tumor, LXR activation limited 
neoplastic progression, thus representing a novel promising therapeutic target to uncouple 
regeneration and tumorigenesis.  
Taken together, this thesis contributes to our understanding on how ILC and cholesterol 
metabolism modulate intestinal barrier function and integrity.  
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1 INTRODUCTION 
The intestinal tract represents a highly vulnerable barrier site due to its broad exposure to a 
massive amount of foreign antigens present in the lumen 1. Different cell types are involved 
in preserving the physiological function and integrity of the organ, including immune and 
non-immune cells from the host (such as intestinal epithelial and stromal cells) interacting 
with environmental components. Maintenance of intestinal homeostasis requires tightly 
coordinated pro-inflammatory and tolerogenic responses 1. While pro-inflammatory intestinal 
immune responses ensure protection against clinically relevant pathogens, the establishment 
of immunological tolerance avoids immune reactions against innocuous antigens 2. 
Disruption of this delicate balance is a hallmark of intestinal pathologies, such as food 
allergies or inflammatory bowel disease (IBD) 3, characterized by chronic uncontrolled 
inflammation and impaired tissue repair.  
 
The intestine as an “immunological” organ: overview. The intestine is characterized by a 
single layer of intestinal epithelial cells (IECs) at the interface between the luminal 
environment and the mammalian host. The epithelium is composed of stem cells, absorptive 
enterocytes and specialized secretory IECs that embody the physical and biochemical barrier 
protecting the underlying tissue 3. One of the main functions of secretory IEC is to produce 
mucus 4 and antimicrobial peptides (AMPs) 5, generating a barrier to keep bacteria at bay. 
Together with epithelial cells, the immune system contributes to generate an efficient barrier 
and protection against pathogens. Interspersed between epithelial cells, intraepithelial 
lymphocytes (IELs), composed mainly by T cells and type 1 innate lymphoid cells (ILC1), 
help maintaining barrier integrity and protection against pathogens 6,7. Underlying the 
epithelium basement membrane, the lamina propria is a loose connective tissue where the 
majority of the intestinal immune cells are located, embedded in a stromal architecture. 
Strategically located adjacent to the epithelium, intestinal mononuclear phagocytes, 
comprising macrophages (MΦ) and dendritic cells (DC), actively sample luminal antigens 
and coordinate the immune response locally or upon migration to draining lymphoid tissues 8. 
Together with abovementioned immune cells, other myeloid (including neutrophils, 
monocytes, mast cells, eosinophils) and lymphoid cells are found in the intestinal lamina 
propria.  
Adaptive immune responses (including B and T cell responses) are originated in lymphoid 
structures, such as the mesenteric lymph node (MLN) and the gut-associated lymphoid tissue 
(GALT), including Peyer’s patches and isolated lymphoid follicles (ILF). Upon activation in 
lymphoid organs, T and B cells migrate and localize in the intestinal tissue where they exert 
non-redundant effector functions aimed at maintaining intestinal homeostasis 9.  
Another more recently identified class of innate lymphocytes, named innate lymphoid cells 
(ILCs), is highly enriched in the gastrointestinal mucosa. ILCs are mucosal gatekeepers 
playing a pivotal role in ensuring barrier homeostasis 10. In the sections to be followed, the 
development, function and adaptation to the environment of ILCs is discussed.  
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2 INNATE LYMPHOID CELLS 
2.1 ILC classification and function 
ILCs are a class of lymphocytes, often defined as the innate counterpart of T cells, with 
pleiotropic functions at the barrier sites of our body 11. Despite the high degree of overlap 
with T cells, ILCs do not react in antigen-specific manner 12, do not rely on priming in 
secondary lymphoid organs (SLO) and their innate nature enables a kinetically faster 
response in tissues driven by sensing of stimuli like cytokines, alarmins, stress signals or 
hormones 13. ILCs are relatively more represented in mucosal and barrier tissues, likely due 
to their ability to translate environmental and inflammatory cues into an effector program 
preventing pathogen-mediated damage, favoring tissue repair and contributing to tissue 
homeostasis.  
Although natural killer (NK) and lymphoid tissue-inducer (LTi) cells have been identified 
many years ago 14,15, the discovery of novel ILC lineages and a comprehensive and unified 
classification of ILCs have drastically advanced only in the last decade 11. ILCs are 
subdivided into two main lineages: cytotoxic ILCs (comprising NK cells) and helper ILCs 
(composed of three main subsets, ILC1, ILC2 and ILC3). Mirroring the well-established T 
cells classification system, NK cells are proposed to be innate counterpart of CD8+ T cells 
and ILC1, ILC2 and ILC3 of T helper (Th) 1, Th2 and Th17 cells respectively 16. In line with 
this approach, master transcription factors and cytokine production defining each subtype (as 
outlined below) display a high degree of overlap between T cells and ILCs. However, as in 
the field of T cells, technological advancement allowing transcriptional analysis at the single 
cell level and lineage tracing tools unearthed a high degree of heterogeneity and plasticity 
converting this well-defined genealogic tree into a more dynamic continuum 17,18. 
Remarkably, an innate counterpart of regulatory T cells (Treg) has long been missing. 
Recently, a population of regulatory ILCs (named ILCreg) expanding in the intestine in 
response to inflammation has been identified. ILCregs are characterized by interleukin (IL-) 
10 expression, by which they inhibit inflammatory cytokines production by ILC1 and ILC3 
19. Whether these cells represent an independent subset or rather a transient functional state of 
other ILC subsets remains unresolved. Nevertheless, other helper ILCs (such as ILC2 and 
ILC3) can play immunoregulatory functions, thus representing an unconventional innate 
counterpart of Treg cells. In the following paragraphs a brief description of the different ILCs 
lineages is outlined (Figure 1). 
2.1.1 NK cells 
The discovery of NK cells dates back to the mid-1970s, when Kiessling, Klein and Wigzell at 
Karolinska Institutet described for the first time a class of naturally occurring cytotoxic 
lymphocytes specific for leukemia cells 20. NK cells are generally characterized by the 
expression of the transcription factor T-bet and Eomesodermin (i.e. Eomes) driving interferon 
(IFN)-γ and perforin and granzyme B expression respectively 21. Similar to ILC1s, NK cells 
participate in the immune response against intracellular pathogens (such as viruses) and 
tumor immunosurveillance and are geographically highly enriched in the liver tissue 22. They 
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are equipped with activating (e.g. CD16) and inhibitory receptors (e.g. Ly49 and KIRs) 
modulating their cytotoxicity 23. Activating receptors can recognize opsonized or stress-
induced ligands on target cells, while inhibitory receptors detect MHC-I molecules. 
According to the “missing-self” hypothesis 24, lack of MHC-I expression on the surface, 
caused for instance by viral infection or cancerous transformation, fails to engage inhibitory 
receptors thus sensitizing the cell to NK cell-mediated cytotoxic attack. In this fashion, NK 
cells are essential to patrol tissues and limit viral shedding or tumor growth when these 
dangerous insults have hijacked the T cell-mediated recognition machinery 25. 
Unlike NK cells, helper ILCs do not retain cytotoxic potential and, with some exceptions, 
their effector functions mainly rely on the production of soluble mediators, including 
cytokines, growth factors and metabolic mediators 26. In the following paragraphs a short 
outline of the main characteristics of each helper ILC subsets is described. 
2.1.2 ILC1 
Class I ILCs are mainly found in intestine and liver and, similar to NK cells, express the 
transcription factor T-bet, but lack Eomes 27. Mainly upon sensing of IL-12, IL-15 and IL-18 
produced by myeloid and non-hematopoietic cells, ILC1s respond by producing IFN-γ and 
tumor necrosis factor (TNF) 28. Owing to these features, ILC1s have been shown to be critical 
in the response against intracellular pathogens (such as Toxoplasma gondii) 29,30, viral 
infections 31, tumor immunosurveillance 32 and induction of classical macrophage activation 
30. While their pro-inflammatory function aids in protecting the host, the flip side is the 
pathogenic involvement of ILC1 in chronic inflammatory disorders, such as Crohn’s disease, 
where high frequencies of ILC1 are found in the intra-epithelial compartment of the gut 
mucosa 7,33. In humans, a high degree of heterogeneity in ILC1s has been recently detailed 
via single cell transcriptomic analysis and mass spectrometry in different anatomical sites, 
likely reflecting the tissue adaptation of ILC1 functions 17,34. 
2.1.3 ILC2 
Group 2 ILCs are essential mediators of type2 immunity thus conferring resistance to 
helminth infections (such as Nippostrongilus brasiliensis in lungs and gut) 35,36 and 
promoting tissue repair. ILC2s are identified by high expression of the transcription factor 
GATA-3, essential to regulate their function and development 37. Found predominantly in 
lungs, intestine, adipose tissue and skin, ILC2s respond to the epithelium-derived cytokines 
IL-33, IL-25, TSLP (thymic stroma lymhpopoietin) and to IL-4 and arachidonic acid 
metabolites 38. Their effector programs rely on the production of the cytokines IL-9, IL-5 and 
IL-13 and of the epithelial growth factor amphiregulin (Areg) 39. By producing these 
mediators, ILC2s can establish a crosstalk with immune and non-hematopoietic cells, thus 
driving tissue homeostasis and adaptation to external insults. For instance, in the context of 
inflammation/infection, epithelial cell death leads to release of the alarmin IL-33 sensed by 
IL-33 receptors (also known as ST2) on ILC2s resulting in their production of Areg 40. In turn 
Areg signals on intestinal epithelial cells driving their proliferation and mucus-producing 
 12 
goblet cells differentiation 40. This pathway has been studied in the context of protection 
against intestinal inflammation 40, skin wound healing 41 and promotion of tissue repair and 
airway epithelial integrity following H1N1 influenza virus infection in the lungs 42. Another 
example of immune-epithelial cells crosstalk mediated by ILC2s is the production of IL-13 in 
response to intestinal epithelial cells sensing of helminth infections. Tuft cells, chemosensory 
brush cells present in intestinal epithelial villi, are exclusive producers of the cytokine IL-25 
upon parasitic infection 43. Via the expression of IL17Rb (also known as IL-25 receptor), 
ILC2s respond to IL-25 by producing IL-13, which in turn skews intestinal stem cells 
differentiation towards tuft and goblet cells 44,45. This positive feedback loop orchestrated by 
ILC2s enables a reprogramming of epithelial cells composition leading to a more competent 
barrier for the expulsion of large pathogens. Indeed, IL-13 driven mucus production by goblet 
cells and smooth muscle cells contraction are essential to remodel the tissue and expel worms 
from the gastrointestinal tract 46,47. Therefore, by establishing a dynamic crosstalk with non-
hematopoietic cells, ILC2s drive homeostasis in tissue- and context-specific manner. In line 
with this, ILC2s display a high degree of functional adaptation dependent on their 
geographical location. Single cell RNA sequencing of ILC2s from different organs revealed a 
high degree of heterogeneity in the expression of cytokines and alarmin receptors. For 
instance, while Gata-3 expression is a common feature of all ILC2s regardless of the tissue, 
IL-33 receptor (Il1rl1) expression defines fat and lung ILC2s, IL-25 receptor (Il17rb) is 
mainly expressed by gut ILC2s and skin ILC2s are marked by the expression of IL-18 
receptor (Il18r1) 48. These findings suggest that the tissue environment functionally shape 
ILC2 identity and in turn tissue adaption of ILC2s is required to maintain homeostasis in 
different anatomical location.  
While the aforementioned effector program of ILC2s is pivotal to re-establish homeostasis, 
exacerbation of ILC2s activation can backfire and drive the pathogenesis of several 
inflammatory disorders affecting the lungs (such as asthma, chronic sinusitis with nasal 
polyps, lung fibrosis) 49,50,51,52, the gastrointestinal tract (e.g. eosinophilic esophagitis) 53 and 
the skin (as in atopic dermatitis) 54. In these disease settings uncontrolled cytokine production 
by ILC2s leads, for instance, to unrestrained goblet cells hyperplasia and consequent mucus 
production with deleterious consequences for normal airway functions 39. In addition, ILC2s 
can orchestrate the response of other immune cells ultimately feeding the inflammatory 
process 55,56. 
2.1.4 ILC3 
Class 3 ILCs are a heterogeneous group of ILCs mainly enriched in the intestine, skin and 
tonsils. The common denominator of all ILC3s is the expression of the transcription factor 
RAR-related orphan receptor gamma t (RORγt), essential for their ontogenesis and function 
57. Belonging to this class are LTi, critical mediators of fetal lymphoid tissue organogenesis, 
and two other subsets of ILC3s identified based on the expression of natural cytotoxicity 
receptors (NCR), CCR6 and T-bet 58. In mice, adult LTi-like CCR6+ T-bet- ILC3s do not 
express NCRs and are mainly located in intestinal cryptopatches and ILFs where they can 
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produce the cytokines IL-22, IL17A and IL17F. CCR6- T-bet+ ILC3s instead, express the 
NCR NKp46 and CD49 and produce mainly IL-22. In humans, NCR- and NCR+ ILC3s are 
distinguished based on the expression of NKp44. In the following paragraphs a brief outline 
of the function of LTi, adult LTi-like, NKp46+ ILC3s and of common ILC3 functions is 
provided.  
LTi and adult LTi-like cells in lymphoid tissue organogenesis. LTi and LTi-like cells are 
essential mediators of lymphoid organ formation both during fetal development and in post-
natal life. LTi cells are originated in the fetal liver and are found in lymph nodes (LN) 
anlagen, where they coordinate lymphoid organogenesis, during embryonic development 
(day E13.5) 15,59. How LTi’s recruitment and positioning at the site of LN formation is 
regulated is still poorly understood. The recruitment of LTi to LN anlagen seems to be 
mediated by the chemokine receptor CXCR5 sensing the chemokine CXCL13 produced by 
stromal organizer cells, a stromal population driving LN organogenesis 60,61. Interestingly, 
production of retinoic acid (RA), by nerve endings might be needed to guide the production 
of stromal CXCL13 and thus the recruitment of LTi 62. This finding suggests that neuron-
derived signals and sites of RA release are pivotal in determining the location of LN 
formation at the embryonic stage. Together with CXCL13, CCL21 expression by the 
lymphatic endothelium aids in attracting LTi cells through their expression of the cognate 
receptor CCR7 63. Once in the LN anlagen, owing to their expression of TNF-related 
activation-induced cytokine (TRANCE) and TRANCE receptor (TRANCER), LTi cells 
cluster and signal in trans leading to the induction of lymphotoxin-α1β2 (LTα1β2) expression 
64. Interaction between LTα1β2 and its receptor lymphotoxin-β-receptor (LTβR) on stromal 
cells promotes the differentiation of the latter into stromal organizer cells, mesenchymal cells 
capable of giving rise to the different mature stromal cell subsets found in mature LN 65. 
Signaling through LTβR results in the production of the adhesion molecules vascular cell 
adhesion molecule 1 (VCAM1), intercellular adhesion molecule 1 (ICAM1) and mucosal 
vascular addressin cell adhesion molecule 1 (MAdCAM1) as well as the chemokines CCL19, 
CCL21 and CXCL13 66,67, all necessary for the recruitment and retention of other 
hematopoietic cells constituting mature lymphoid organs.   
Mucosa-associated lymphoid tissues, with the exception of Peyer’s patches 68 and unlike 
other lymph nodes, develop after birth 69. Cryptopatches, formed around 2 weeks after birth 
in mice, are small clusters of adult LTi-like cells, dendritic cells and stromal cells dispersed in 
the intestinal lamina propria in close proximity with the intestinal epithelium 70,71. Upon 
CCR6-mediated B cell recruitment, cryptopatches enlarge giving rise to ILF, also known as 
large solitary isolated lymphoid tissues (SILTs) 72. Similar to other LN, cryptopatches 
development relies on lymphotoxin signaling but, in addition, owing to their mucosal 
location, signals from the intestinal flora seem to play a role in the genesis of large SILT. In 
particular, commensal bacteria-derived signals were described to induce CCL20 production 
by ileal intestinal epithelium, conceivably promoting CCR6-mediated B cells attraction 73. 
However, which signals control specific LTi-like cells recruitment in cryptopatches 
(especially in the colon) as opposed to other mature ILC3s, mainly dispersed in the lamina 
propria, remain largely unexplored. In the second manuscript included in this thesis, we have 
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described a novel role for the G protein-coupled receptor (GPR) 183 (also known as Epstein-
Barr virus-induced gene 2, EBI2) in driving attraction and retention of CCR6+ ILC3s in 
cryptopatches and ILF (see “Results”).  
Adult LTi-like ILC3s, by accumulating in the interfollicular regions of lymphoid clusters 74,75, 
are geographically favored to interact with T and B cells and thus modulate adaptive immune 
responses. Indeed, via the expression of MHC-II and the lack (or low expression) of co-
stimulatory molecules CD80 and CD86, adult LTi-like ILC3s induce immune tolerance by 
promoting cell death of commensal-specific CD4+ T cells 76,77. On the other hand, owing to 
the expression of the costimulatory molecules OX40L and CD30L, they can aid the survival 
of memory CD4+ T cells and favor T cell-dependent antibody production by B cells 78. In the 
intestine, adult LTi-like ILC3s have been shown to be critical to drive IgA response by B 
cells in a T cell-dependent and independent manner 71. Mechanistically, by expressing 
LTα1β2 and secreting LTα3, BAFF and APRIL, ILC3s fuel B cell activation and production 
of IgA, which is critical to control commensals and pathogens containment in the lumen 79,80. 
Hence, by orchestrating the intestinal adaptive immunity and commensal-specific T cell and 
IgA response, LTi-like ILC3s are important gatekeepers of mucosal homeostasis 81. 
Moreover, their strategic positioning in cryptopatches at the bottom of intestinal epithelial 
crypts and their ability to produce the IL-22 renders them key mediators of stem cells pool 
maintenance and tissue repair in response to damage (see below for the role of IL-22 in 
intestinal homeostasis) 82.  
NKp46+ ILC3s in the intestine are mainly found interspersed in the lamina propria, owing to 
their expression of the chemokine receptor CXCR6 interacting with CXCL16 produced by a 
subset of IL-23-producing DCs. This CXCR6-CXCL16 axis mediates the functional 
topography of IL-22+ ILC3s in the gut which in turn is required to achieve successful 
protection against pathogens, such as Citrobacter rodentium 83. While sharing with the LTi-
like ILC3s subset the expression of RORγt and IL-23 receptor, NCR+ ILC3s rely on Il12rb2, 
Tbx21 (encoding for T-bet) and Notch1 for their development 84,85,58 and express the 
cytotoxicity receptor NKp46 (in mouse) and NKp44 (in human), which are suggested to 
function as pattern recognition receptors to mount inflammatory responses 86 and protect 
against pathogens 87. Given their expression of T-bet and IL-12 receptor, a high degree of 
plasticity towards class 1 ILCs has been attributed to this subset of ILC3s. Fate-mapping 
experiments uncovered a population of T-bet+ NKp46+ cells that had lost RORγt expression 
and acquired a functional phenotype resembling ILC1 84. Further suggesting plasticity, 
Crohn’s disease patients display higher proportion of CD14+ DCs that boost the conversion of 
ILC3 to inflammatory ILC1 in vitro via the production of IL-12. Conversely, culturing ILC1 
in the presence of IL-23, IL-1β and RA favors their conversion to ILC3s 88.  
Behind this dichotomous distinction of peripheral adult ILC3 subsets, many other populations 
of ILC3s have been identified through the use of deep-sequencing approaches with single-cell 
resolution both in mice and humans 18,17. Many of these newly identified subsets might likely 
represent distinct functional or developmental states of the same class of cells rather than an 
ontogenically and functionally distinct subset. In human tonsils, for instance, a subset of 
ILC3s expressing CD62L and poorly responding to re-stimulation has been identified 89. 
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Given their naïve-like phenotype, this subset possibly represents a developmental ancestor of 
mature and activated ILC3s 90. 
ILC3s function can be highly influenced and shaped by the environment, particularly by 
nutrient-derived signals 91. For example, RA controls the transcription of Il22 in ILC3s 92, 
while a vitamin A depleted diet causes drastic reduction of ILC3 numbers and, as a 
consequence, impaired protection against C. rodentium infection 36. Moreover, maternal 
retinoid intake shapes the development of fetal LTi cells in utero, thus controlling the size of 
lymphoid organs and the ability to mount protective immunity in the adult offspring 93. 
Another receptor expressed by all ILC3s, the aryl hydrocarbon receptor (AhR), can sense diet 
derived AhR ligands present in cruciferous vegetables 94. Mice lacking AhR or adult 
offspring of pregnant mice fed with AhR ligand-depleted diet display a significant reduction 
in CCR6- ILC3s coupled with reduced expression of IL-22, thus leading to enhanced 
susceptibility to C. rodentium infection 95,96. Overall, these data indicate that innate immune 
protection mediated by ILCs can be pre-programmed as early as at the embryonic stage and, 
in parallel, mature ILCs can adapt to changes in the microenvironment and nutritional uptake. 
Cholesterol, a key component of cell membranes and metabolic precursor, can be synthetized 
by the liver or absorbed through the diet. In particular, “Western diet”, epidemiologically 
associated to many inflammatory diseases, is highly enriched in cholesterol. Whether 
cholesterol can shape ILCs functions remains elusive. In the second manuscript included in 
this thesis, we have unraveled a novel role for cholesterol metabolites in the regulation of 
ILC3 migration and function in colonic cryptopatches.  
A shared effector function among virtually all ILC3 subset is the production of the cytokine 
IL-22. IL-22 is a member of the IL-10 superfamily 97 and, unlike most other cytokines, 
targets nonhematopoietic cells. IL-22 receptor (composed of IL-10R2 and IL-22R1 subunits) 
is expressed on intestinal epithelial cells; hence this cytokine represents a strategic mediator 
of immune-epithelial crosstalk to control mucosal homeostasis. As hinted above, promotion 
of IL-22 production is driven by a plethora of heterogeneous stimuli encompassing diet (e.g. 
RA, AhR ligands) 92,98, cytokines (IL-23 and IL-1β) 99,100, microbial flora 101,102 and 
transcription factor requirements (RORγt in mice) 101. Early studies proved that IL-22 plays a 
central role in the protection against intestinal bacterial and viral infection. Molecularly, IL-
22 synergizes with IFN-λ signaling to curtail rotavirus infection 283 or promotes the 
production of AMP by intestinal epithelial cells, specifically lectins of the Reg3 family, 
necessary to restrain attaching and effacing bacterial pathogens (such as C. rodentium) 103. 
Adding to this body of evidence, in the second study included in this thesis, we have shown 
that cholesterol metabolites sensing through EBI2 enables ILC3 migration to colonic 
cryptopatches and, as a consequence, impact their ability to produce IL-22. In line with our 
findings, another group has shown that mice lacking GPR183 display reduced protection 
against C. rodentium infection as a result of reduced numbers of IL-22+ ILC3s 104. Together 
with its anti-microbial role, IL-22 is considered as one of the main pro-regenerative cytokines 
by favoring tissue repair. Using different intestinal epithelial cell damage models, including 
chemotherapy 105, graft-versus-host disease 106,107 or chemically induced colitis 108,109, several 
studies demonstrated the pro-regenerative role of IL-22. Mechanistically, sensing of IL-22 by 
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intestinal stem cells drives signal transducer and activator of transcription 3 (STAT3) 
phosphorylation and regulation of anti-apoptotic and pro-proliferative pathways 82. 
Altogether, these studies propose a model where, by ensuring protection against pathogen 
invasion and gatekeeping an intact lining of the epithelial barrier, IL-22 acts as a central node 
in maintenance of intestinal homeostasis. Nonetheless, a tight control of IL-22 level is a 
prerequisite to prevent uncontrolled growth of intestinal stem cells. Indeed, incautiously 
boosting pro-regenerative pathways comes at the risk of fueling unrestrained proliferation of 
stem cells and enhancing the possibility of accumulating malignant transformations. In line 
with this, IL-22 has been shown to drive tumor progression in the small intestine in the 
genetically-driven ApcMin/+ mouse tumor model 110. To overcome this menace, our body has 
evolved a system to maintain IL-22 levels in check. Production of IL-22 binding protein 
(BP), a soluble receptor that neutralizes IL-22 activity, towards the end of the regenerative 
process has been proven critical to restrain tumor development in the colon 110. Nevertheless, 
a more complex picture of IL-22 contribution to colonic tumorigenesis is now emerging. A 
recent study elegantly showed that IL-22 sensing by intestinal stem cells promotes the DNA 
damage response, a machinery that controls genome integrity and dampens malignant 
transformation 111. Reconciling these data, a dual role of IL-22 as anti- and pro-tumorigenic 
might rely on the kinetics of expression in specific contexts and/or the organ system and 
tumor model used.  
 
Figure 1. Schematic representation of ILC subsets and function. 
 
 
  17 
2.2 ILC development 
Several groups over the last decade have focused on unearthing when, where and how ILCs 
development takes place. Of late, different ILC precursor populations have been identified in 
mouse and human, both during the fetal stage and in adulthood. The current model of ILC-
poiesis propose a step-wise specification where progenitors harboring a broader 
differentiation potential sequentially lose multipotency, ultimately leading to committed 
precursors and differentiated mature ILCs 112 (Figure 2). 
Fetal ILC development. Development of ILCs begins during the fetal period in the fetal liver 
and intestine 113. An ILC precursor expressing Arginase 1 (Arg1), CD127 (the receptor for 
IL-7) and the integrin α4β7 present in the fetal intestine has been proven capable of 
generating all three types of ILC lineages in vitro in the presence of OP9 feeder cells 114. 
Similarly, a progenitor population named α-LP, as an acronym of α4β7+ Lymphoid 
Precursor, expressing CD127 and DNA-binding protein inhibitor 2 (Id2), was identified by 
single cell analysis in the fetal liver as the most primitive ancestor capable to generate all 
helper ILC subsets and LTi cells 115. Despite the presence of these multipotent ILC 
progenitors, the fetal period appears to be the main stage for ILC3, and more specifically LTi 
development. Two groups have identified a population of α4β7+ RORγt+ CXCR6+ cells in 
the fetal liver endowed with LTi differentiation potential in a Notch-independent manner 
116,117. Furthermore, single cell analysis of fetal liver progenitors identified a population 
marked by the expression of CXCR5 and the lack of PLZF, coinciding with LTi progenitors 
(LTiP) 115. Less is known regarding the fetal development of other ILC subsets, such as ILC1 
or ILC2. Recently, a fate-mapping study of mature ILC2s in different peripheral tissues 
revealed that the majority of ILC2 pools are generated de novo during the post-natal window, 
and only a minor fraction of peripheral mature ILC2s are derived during the late gestation 
period 118. The diverse kinetics of ILC subset development might reflect their differential 
contribution to physiology. In line with this hypothesis, lineages involved in organogenesis 
(such as LTi driving lymphoid organogenesis) require pre-natal development while subsets 
involved in organ homeostasis display a delayed differentiation (post-natal period). 
Adult ILC development. In adulthood the bone marrow (BM) is considered as the cradle for 
ILC development. Starting from common lymphoid progenitors (CLPs), different precursors 
that had lost B and T cells potential and are uniquely committed to ILCs have been recently 
described. Specific surface markers, transcription factor requirements and differentiation 
potential mark these diverse populations of ILC progenitors. Interestingly, a common 
denominator of all ILC precursors is the expression of the integrin α4β7, which binds to 
MAdCAM1 and is widely considered as a gut-homing receptor. While α4β7 was shown to be 
important for migration of ILC2 upon development from the BM to the intestine 119, its role 
on the other multipotent ILC precursors remains unclear.  
A direct ancestor-progeny relationship among the different ILC precursors identified thus far 
is still missing, as their discovery arose from different studies. In the next paragraphs an 
attempt to describe in genealogic order (and not the chronological order of discovery) the 
different ILC progenitors is presented.  
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Figure 2. Schematic representation of ILC development 
2.2.1 EILP 
The most primitive ILC ancestor, retaining the potential to differentiate to all ILC lineages 
(helper and cytotoxic) was named early innate lymphoid progenitor (EILPs). EILPs are 
marked by the expression of α4β7 and the transcription factor T cell factor-1 (TCF-1, 
encoded by the gene Tcf7). However, unlike other ILC precursors, EILPs lack the expression 
of CD127, CD90 and of markers specific for committed progenitor populations (such as 
CD122 for NK progenitors or CXCR6 for helper ILC precursors). Mice deficient in Tcf7 
display a cell-intrinsic severe defect in the generation of all mature ILCs and of committed 
ILC progenitors, thus locating EILP at the top of the ILCs genealogic tree. Vice versa, 
isolated EILPs were able to generate all known ILC subsets both in vivo and in vitro at a 
clonal level 120. Together with Tcf7, other molecular players are important to regulate ILC 
development. Nuclear factor interleukin 3-regulated (NFIL3), a transcriptional regulator 
involved in multiple hematopoietic lineages and in circadian rhythm, appears to be important 
at the early ILC precursor, as Nfil3-/- mice display severe impairment in the generation of all 
ILC subsets (including cytotoxic and helper ILCs) 121. Downstream NFIL3, the transcription 
factor thymocyte selection-associated high mobility group box protein (TOX) has also been 
proven necessary for early ILC lineage specification 122. 
Downstream EILP, the bifurcation into NK-committed progenitors (NKP, expressing CD122 
123 Eomes and T-bet 124) and helper ILC precursors seems to take place. 
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2.2.2 CHILP 
Common helper ILC progenitors (CHILPs) were identified based on the expression of α4β7, 
CD127, c-Kit, the transcription factor Id2 and the absence of lineage markers (specific for 
other mature immune cells population), CD25 (the receptor for IL-2, marking committed 
ILC2 precursors) and the receptor FMS-like tyrosine kinase 3 (Flt3, also known as CD135, 
which marks CLPs). This pool of ILC precursors retains the ability to generate all helper 
ILCs (including LTi) both in vivo and in vitro and lack NK differentiation potential. 
Remarkably, CHILPs appear to be a heterogeneous population, comprising multiple 
progenitors, as seen by their ability to generate single and mixed colonies of different ILC 
lineages upon single-cell culture in vitro 30. While the first identification of CHILPs was 
achieved through the use of Id2-GFP reporter mice, a recent study utilizing Id2-RFP mice 
challenged the current view of CHILP as progenitors committed to helper ILCs and lacking 
NK potential. This novel reporter mouse showed a more robust fluorescence staining 
(compared to GFP) and was generated retaining the endogenous expression of Id2, thus 
allowing a more sensitive analysis. Using Id2-RFP mice, the authors showed that Id2-
expressing ILC precursors still retain the ability to generate NK cells both in vitro and in vivo 
125. Id2, belonging to the ID family of transcriptional repressors, heterodimerizes and thus 
inhibit the function of E2A, a transcriptional activator required for adaptive lineage 
progression 126. In this fashion, Id2 upregulation sets the stage for commitment to ILCs and 
repression of B and T cell potential. 
2.2.3 ILCP 
After CHILPs, the bifurcation into LTiP and ILC precursors (ILCP) committed to all the 
other helper ILC subsets is suggested to take place. ILCPs are identified based on the 
expression of promyelocytic leukemia zinc finger (PLZF, encoded by the gene Zbtb16), a 
transcription factor originally studied in NKT cells development. Fate mapping experiments 
showed that ILC1, 2 and 3 but not LTi or NK cells had a history of PLZF expression, thus 
allowing the identification of ILCP in the BM based on the co-expression of PLZF, α4β7, 
CD127 and c-Kit. In line with the lineage-tracing results, this progenitor population was 
shown to give rise to all helper ILCs (but LTi) both in vitro and in vivo 127. 
2.2.4 Committed ILC precursors 
Downstream ILCP, unipotent ILC precursors committed to the different lineages have been 
described. How and where this fate decision takes place remains still largely unresolved. 
Single cell analysis of fetal ILC progenitors and hierarchical clustering proposed a model 
whereby, instead of a direct commitment to a specific lineage, ILCPs undergo a stage of 
simultaneous effector programs expression followed by progressive shut down of programs 
for alternative fates 115. A committed precursor to ILC1 (ILC1P) has been identified in the 
murine BM based on the expression of CD127, NKp46, NK1.1 and the lack of Eomes and 
RORγt expression. This population represents a bona fide immature ILC1 population as 
shown by their ability to uniquely give rise to ILC1 both in vitro and upon adoptive transfer 
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in lymphopenic mice in vivo 30. Unlike other subsets, ILC2 committed precursors (ILC2P) in 
the BM are largely represented. ILC2P are characterized by the expression of α4β7, CD127, 
CD25 and are reliant on the transcription factors GATA-3, TCF1 and RORα for their 
development 35. While GATA-3 appears to be required for all helper ILCs development, a 
marked upregulation of its expression marks the commitment of ILCP to the ILC2 lineage 128 
37. Despite the high degree of phenotypic overlap with mature ILC2s, ILC2P in the BM are 
considered as progenitors based on their higher proliferative capacity and limited cytokine 
production potential in the absence of differentiating stimuli 37. Interestingly, ILC2P in the 
BM express the chemokine receptor CCR9, which in conjunction with α4β7 expression 
drives ILC2P relocation and differentiation in the intestinal lamina propria, thus suggesting 
an organotropic specific imprinting already during ontogenesis 37. Remarkably, after initial 
colonization of peripheral organs, occurring mainly in the post-natal/adult period, ILC2s 
seem to expand in situ following infection rather than depending on de novo BM ILC-poiesis 
118. These findings raise questions on the purpose of maintaining a relatively large population 
of ILC2P in the BM throughout life. A possible explanation is that ILC2P in the BM are 
rather a functionally mature ILC2 population playing a specific function in the BM niche 
rather than a committed immature progenitor.  
While committed precursors to LTi cells in the fetal liver were the first ones to be identified, 
much more challenging was the identification of other ILC3 precursors (ILC3P). Indeed, 
unlike ILC2P and ILC1P, ILC3P are highly infrequent in the adult BM. Nevertheless, a 
recent study making use of polychromic multiple reporter (Id2, RORα, Bcl11b, Gata-3 and 
RORγt) mice allowed the identification of an extremely rare population of ILC3P based on 
the expression of RORγt, Id2, Bcl11b and the low expression of GATA-3 129. The paucity of 
ILC3P in the adult BM has been justified by the hypothesis that early immature ILCP on their 
way to become ILC3 leave prematurely the BM and complete their maturation in peripheral 
organs 112. An alternative explanation might be that we haven’t yet found BM ILC3P and we 
should approach this question in an unbiased fashion rather than exploiting known markers of 
ILC precursors for their identification. 
2.2.5 Human ILC development 
In humans attempts to draw an analogous map of ILC development has been performed over 
the last decade. A common human ILC precursor has been identified in secondary lymphoid 
organs (tonsil and spleen), although absent in cord blood, peripheral blood, thymus or BM. 
These progenitors are marked by the expression of CD34, CD45RA, CD117, IL-1R1, 
integrin β7 and RORγt and display the potential to differentiate into NK and all helper ILC 
subsets in vitro 130. Downstream this multipotent population, committed progenitors to the 
NK lineage and to ILC3s have also been characterized in humans. NKPs were identified in 
the fetal liver, fetal BM, cord blood and adult tonsil by the expression of CD34, CD45RA, 
CD10, CD7 and the lack of CD127 131. ILC3-committed precursors, instead, were discovered 
in tonsils and in the intestinal lamina propria based on the expression of CD34, CD45RA, 
CD117, α4β7, RORγt, ID2, KIT, NCR1 and the lack of CD7 and CD127 132. While 
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remarkably similar to common ILC precursors identified in SLOs, ILC3Ps are distinguished 
based on the lack of IL-1R1. 
2.2.6 Tissue residency of mature ILCs 
Despite the existence of ILC precursors in the adult BM, the current consensus proposes that 
the pool of peripheral mature ILCs is maintained independently from BM lymphopoiesis. 
Indeed, by using parabiotic mice, Rudensky’s lab showed that mature ILCs are tissue resident 
cells, lingering in peripheral tissues for long period of time (up to 130 days) under 
homeostatic conditions 133. This finding is hard to reconcile with the evolutionarily conserved 
energetic expenditure to maintain pool of ILC progenitors in the adult BM. However, in the 
same study the authors showed that in the context of chronic infections, cells of 
hematogenous source were partially replenishing the tissue at a late stage 133. On a similar 
line, another report from Germain’s lab demonstrated that ILC2s from the intestinal lamina 
propria are endowed with the ability to relocate to the lungs under inflammatory conditions 
134. In parallel, human common ILC progenitors, characterized by IL-1R1 expression, have 
been shown to respond to IL-1β with enhanced proliferation and differentiation 135. These 
results led to the postulation of a model whereby, while mature ILCs largely depend on in situ 
self-renewal under homeostatic condition, an “on demand” ILC-poiesis or tissue relocation 
takes place upon inflammation (such as infection in mice or IL-1β production in humans) 136. 
In the first manuscript included in this thesis, we have expanded on this model and showed 
that ILC precursors in the adult BM can respond to increased systemic levels of the 
inflammatory cytokine Flt3L. This phenomenon might represent the lymphoid counterpart of 
the previously described “emergency myelopoiesis” 137. 
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3 INTESTINAL EPITHELIAL CELLS 
The intestinal epithelial barrier is organized as a single layer of epithelial cells constituting 
the very first cellular shield facing the external environment and physically separating the 
luminal content from the host underneath. The main functions of intestinal epithelial cells are 
absorption of nutrients while ensuring protection against biotic and abiotic environmental 
stressors. To fulfill these two opposing tasks, the intestinal epithelium has evolved a system 
to maximize its surface of interaction with the environment (amplifying absorption) and, at 
the same time, shelter this vast barrier from external insults. The architectural organization in 
crypt-villus structures and the continuous regenerative behavior of the intestinal epithelium 
are the recipes to embody this dual role.  
Crypt-villus architecture and continuous regeneration. The small intestinal epithelium is 
composed of crypt-villus units, where the first one represents an invagination, while the latter 
is a finger-like protrusion of the intestinal wall. The colon, instead, completely lacks villi and 
is composed of elongated crypts only. The villus is primarily composed of absorptive 
enterocytes devoted to absorb nutrients. However, by projecting into the lumen, they are 
constantly exposed to mechanical and environmental stressors. To warrant protection, 
enterocytes are post-mitotic cells with a remarkably short lifespan (3-5 days). This way, our 
body continuously gets rid of potentially damaged and infected cells and avoids inheritance 
of stress signals or mutations to daughter cells. To ensure constant replenishment of 
enterocytes, the crypts (also called crypts of Lieberkühn) host the factory continuously 
generating all the differentiated epithelial cells. In this fashion, actively proliferating cells are 
sheltered from the external environment and hidden in the crypts, while only short-lived cells 
face directly the luminal content. Intestinal stem cells (ISCs), residing at the bottom of these 
invaginations, constantly divide giving rise to highly proliferative progenitors (called transit 
amplifying cells, TA), which then generate all the different mature epithelial cell lineages 
found in the villi. The current consensus proposes a model of passive mitotic pressure along 
the crypt-villus axis to explain the continuous upward movement of epithelial cells. This 
model, also referred as intestinal “conveyor belt”, suggests that when a crypt cell divides, 
pushes the neighboring cells upward thus initiating the journey of enterocytes towards the tip 
of the villus, where they die of apoptosis and are shed into the lumen 138. However, this 
concept was recently challenged by a study proposing that epithelial cells instead migrate 
actively directed by actin-rich basal protrusions 139. 
3.1 The intestinal epithelium: cell type and function 
Originating from ISCs, the intestinal epithelium is composed of six differentiated cell types 
belonging to two lineages: secretory (Paneth, goblet, enteroendocrine and tuft cells) and 
absorptive cells (enterocytes and microfold or M cells). In the following paragraphs, a brief 
outline of the main characteristics of each cell type and of the signals governing maintenance 
and differentiation of the stem cell pool (stem cell niche) is presented. Finally, an overview of 
how epithelial cells adapt and respond to damage is drawn. 
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3.1.1 Paneth cells 
Paneth cells constitute the primary epithelial niche for stem cells proliferation and 
maintenance. Located at the base of the crypt, they are interspersed in between ISCs so that 
each stem cell is in contact with one Paneth cell in a 1:1 ratio. This organization is necessary 
to promote Paneth cell-dependent stem cell activity, reliant on paracrine Wnt production and 
contact-dependent Notch signaling (see below “Intestinal stem cell niche”) 140. Despite being 
a differentiated epithelial lineage, Paneth cells behave quite differently compared to other 
intestinal epithelial cells. Indeed, their lifespan is fairly prolonged (up to 60 days) and they 
are the only ones moving downward rather than towards the tip of the villi upon 
differentiation. This anomalous migration pattern ensures their positioning at the base of the 
crypt and is mediated by EphB2 and EphB3 signaling 141. Besides providing niche factors to 
nurture stem cells, Paneth cells are gatekeepers safeguarding ISCs from external insults. 
Indeed, by producing anti-microbial products, such as α-defensins, lysozyme and 
phospholipase A2, Paneth cells provide a shield protecting ISCs 142. Paneth cells are 
described only in the small intestine and the colon lacks this population. However, a related 
population, named deep crypt secretory cells identified by the expression of regenerating 
family member 4 (Reg4) provides an equivalent function in the large intestine 143. 
3.1.2 Goblet cells 
Goblet cells are secretory epithelial cells devoted to the generation of the mucus layer 
protecting the intestinal barrier. By producing transmembrane mucins (forming the 
glycocalyx) and secreting gel-forming mucins, goblet cells prevent pathogens translocation 
by trapping bacteria 4. Regulating their ontogenesis, while Notch signaling prevents their 
differentiation 144, immune cells-derived interleukins, such as IL-4 and IL-13, boost goblet 
cells hyperplasia 46. Recently, Hansson’s group described a specialized subset of goblet cells, 
called sentinel goblet cells, located at the entrance of the colonic crypt sensing the 
environment through toll like receptors. Upon detection of microbial invasion, sentinel goblet 
cells start secreting mucin 2 (MUC2) and trigger a similar response from all neighboring 
goblet cells 145. 
3.1.3 Enteroendocrine cells 
Enteroendocrine cells (EEC) are specialized hormone producing cells. Among the different 
hormones produced by EEC are gastric inhibitory peptides, somatostatin, cholecystokinin, 
glucagon-like peptides, serotonin and ghrelin. While initially thought to be important for 
nutrients detection and secretion of hormones to stimulate digestion, the role of EEC has now 
been extended to sensors of microbial metabolites and orchestrators of intestinal immunity 
146. 
3.1.4 Tuft cells 
Tuft cells are the taste buds of the intestinal epithelium, for their ability to chemosense 
environmental signals, such as microbial metabolites 147. As described above (see ILC2s), 
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these cells are important mediators of anti-helminth response and orchestration of type 2 
immune responses. By producing IL-25 upon worm infection, tuft cells stimulate IL-13 
production by ILC2s and ultimately skew stem cells differentiation towards tuft and goblet 
cells 43. Recently, intestinal tuft cells have been described to express the succinate receptor 1 
(SUCNR1), necessary to detect succinate metabolites produced by some helminths (such as 
tritrichomonad protists) and thus activate tuft cells cytokine production 148. 
3.1.5 Enterocytes and M cells 
Absorptive enterocytes constitute the majority of the differentiated epithelial cells. They 
populate the villi where they mediate nutrient (lipid, sugar, water, peptide and ion) 
absorption. They are derived from absorptive progenitors in a Notch signaling-dependent 
manner 149. M cells, instead, are a specialized epithelial lineage found specifically above 
Peyer’s patches. These cells are responsible for uptake and transfer of luminal antigens to the 
immune cells underneath 150. Their differentiation is dependent on receptor activator of 
nuclear factor kappa-B ligand (RANKL) produced by subepithelial stromal cells overlying 
the Peyer’s patches 151. 
3.1.6 Intestinal stem cells 
Giving rise to all the differentiated epithelial cells described above, ISCs are multipotent cells 
residing in intestinal crypts. Two main populations of stem cells have been thus far identified 
in the intestinal epithelium, differing based on their location, proliferative potential and 
physiological function.  
CBC stem cells. Crypt base columnar (CBC) stem cells have been identified in the early 
seventies as constantly dividing cells at the bottom of the crypt by Cheng and Leblond 152. 
However, only with the advent of more sophisticated techniques, such as lineage tracing tools 
and specific markers, a deeper functional validation of their stem cell potential was made 
possible. Leucin-rich repeat containing G-protein coupled receptor 5 (Lgr5) was found to 
unequivocally mark CBCs and generation of mouse models to track their progeny allowed to 
prove that these cells are capable of generating all differentiated intestinal cell types for long 
periods of time 153. In parallel, under specific culture conditions, isolated Lgr5+ cells were 
shown to be able to self-renew and generate mini-guts in a Petri dish (called organoids, i.e. 
organotypic cultures composed by crypt-villus structures with all intestinal cell lineages) 154. 
Therefore, owing to their multipotency and ability to self-renew, CBC can be defined as bona 
fide stem cells. CBC cells divide asymmetrically once a day in mice (with an average cell 
cycle time of 21.5 hours) 155 and their location at the bottom of the crypt, immersed in an 
environment of pro-survival niche signals, enables their maintenance of stemness. 
Nevertheless, given the limited space at the base of the crypt, upon division half of the 
progeny is randomly pushed out in a process referred as “neutral competition” 156. Based on 
this model, cells falling out of the niche will start their differentiation path, while CBCs at a 
central and bottom position in the crypts have higher chances to persist longer and maintain 
stemness 157. Over the last decades, expression analysis of sorted Lgr5+ cells enabled the 
identification of a specific CBC gene signature, which includes Achaete-scute complex 
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homolog 2 (Ascl2) 158, tumor necrosis factor receptor superfamily member 19 (TNFRSF19 or 
Troy) 159 and Olfactomedin 4 (Olfm4) 160.  
+4 reserve stem cells. Potten and colleagues described a more quiescent population of label-
retaining cells located above the last Paneth cell in the crypt, at the interphase between the 
crypt base (stem cell zone) and the progenitor zone (where TA cells reside) 161. Owing to 
their positioning four cells above the crypt base, these cells were named +4 cells. In addition, 
due to their enhanced activity in response to damage and limited contribution during 
homeostasis, these cells are also referred as “reserve stem cells”, meaning a pool of stem cells 
that repopulates the stem cell zone when CBCs are ablated upon injury or genetic ablation 
162,163. This concept is consistent with their low cycling nature, which renders them less 
susceptible to damage (such as irradiation). Several markers have been proposed to identify 
this population, including polycomb protein B lymphoma Mo-MLV insert region 1 homolog 
(Bmi1) 164, telomerase reverse transcriptase (Tert) 165, homeobox-only protein (Hopx) 162 and 
leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1) 166. However, the jury is still 
out on whether these can be defined as bona fide +4 cells markers, as they can be found 
expressed by CBCs as well, at least at the transcript level 167,168. 
3.2 Intestinal stem cell niche 
In order to continuously divide and generate a brand new epithelial layer every 3-5 days, 
ISCs rely on signals coming from the surrounding microenvironment, called the intestinal 
stem cell niche. The function of the stem cell niche is to provide signaling molecules, which 
on one hand nurture and foster self-renewal of ISCs and on the other hand promote 
differentiation and positioning of stem cell’s progeny. To be able to serve this scope, niche 
cells are mostly located in direct contact or in close proximity to ISCs at the base of the crypt 
169,170. Belonging to the niche are cells of different origin, encompassing epithelial, 
mesenchymal (fibroblasts, smooth muscle cells, myofibroblasts), enteric neurons and immune 
cells. In the following sections, the main niche signals involved in intestinal stem cell activity 
is briefly discussed (Figure 3). 
3.2.1 Wnt 
Wnt is considered the most important niche factor controlling stem cells maintenance, 
proliferation and, when uncontrolled, tumor formation. Upon secretion, Wnt binds to the 
Frizzled-LRP5-LRP6 receptor complex on ISCs leading to sequestration and inhibition of the 
continuous destruction of β-catenin by the cytoplasmic tumor suppressor adenomatous 
polyposis coli (Apc). As a consequence, the pool of cytoplasmic β-catenin increases and 
translocates to the nucleus where it binds the co-factor T-cell factor (Tcf) and drives the 
transcription of target genes 171. Among the direct target genes of Wnt pathway are c-Myc 
(driving proliferation of undifferentiated cells) 172, Ascl2 (considered as a master regulator of 
stemness) 173, Troy 159, ring finger protein (Rnf) 43 174 and zinc and ring finger (Znrf) 3 175 (all 
considered as negative regulator of Wnt signaling, see below).  
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Proofs of Wnt signaling as fundamental to promote stemness come from studies where 
systemic or conditional knock out of Tcf4 (the main effector of Wnt pathway) result in 
complete loss of stem cells both during neonatal development 176 and in adulthood 177. 
Similarly, mice with overexpression of the secreted Wnt inhibitor Dickkopf1 (Dkk1) in the 
intestinal epithelium phenocopy mice lacking Tcf4 178. Recently, another secreted Wnt 
inhibitor, called Notum, has been identified. Interestingly, Notum levels increase with age 
and inversely correlate with the regenerative capacity of the intestinal epithelium. Thus, 
reduced Wnt signaling explains the progressive loss of regenerative potential observed upon 
aging 179. While inhibition of Wnt signaling strongly affects stemness, on the contrary 
boosting this pathway comes at the risk of promoting uncontrolled proliferation and hence 
fueling tumor formation. Indeed, mice with a heterozygous nonsense mutation in the Apc 
locus (ApcMin/+ mice) develop spontaneous adenomas resembling the human familial 
adenomatous polyposis 180.  
The main sources of Wnt are Paneth cells (producer of Wnt3) in the small intestine and the 
mesenchyme underlying the crypts. Therefore, one may suggest that, Wnt being a vital niche 
factor, having multiple heterogeneous cellular sources ensures functional redundancy that 
prevents loss of this pathway in vivo. Indeed, while Paneth cells-derived Wnt is sufficient in 
vitro to drive organoids growth 140, conditional deletion of epithelial-derived Wnt in vivo does 
not result in any overt phenotype 181. Similarly, deletion of Wnt secretion by myofibroblast 
does not alter the normal intestinal epithelial cells physiology 182. These results indicate that 
there are redundant sources of Wnt in vivo and even if one cell type fails, the system is built 
to preserve this pathway without compromising intestinal homeostasis. Arguing against this 
concept, a recent study identified a peri-cryptal Wnt-producing Foxl1+ stromal population, 
called telocytes, as non-redundant niche cells. Ablation of Wnt secretion by these cells causes 
severe loss of crypt architecture and impaired epithelial renewal 183. 
Wnt bioavailability is tightly controlled and Wnt pathway activation is restricted to the lower 
crypt and decreases while moving upward towards the villus. The way this gradient is 
maintained is via the binding of Wnt to its receptor. Since Wnt is poorly soluble and does not 
freely diffuse, upon secretion by niche cells in the surroundings, it binds immediately to 
Frizzled receptors on ISCs. When ISCs proliferate and differentiate moving upward, they 
bring membrane-bound Wnt with them. However, with every cell division, the amount of 
Wnt on ISC surface is halved, thus establishing a decreasing Wnt gradient when moving 
along the crypt-villus axis 184. Despite being highly concentrated at the bottom of the crypt, to 
ensure a fully functional activation of the Wnt pathway, R-spondins are required. R-spondins 
are soluble proteins that bind to Lgr4 and Lgr5, components of the Wnt receptor on stem 
cells. Upon binding, R-spondin amplifies Wnt signaling and mediates the sequestration and 
inactivation of Rnf43 and Znrf3, ubiquitin-ligases normally mediating Frizzled receptors 
destruction and thus inhibiting Wnt signaling 185,186. 
3.2.2 Notch 
Notch represents a key signaling factor to control cell fate specification within the intestinal 
crypt. Efficient Notch pathway activation requires direct contact between cells expressing 
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Notch receptor on their membranes (Notch 1-4) and cells expressing the transmembrane 
Notch ligands (DSL ligands, Jagged (Jag) 1 and 2, Delta-like (Dll) 1 and 4). Upon ligand 
binding, the Notch receptor intracellular domain (NCID) is released through the proteolytic 
activity of γ-secretases and translocates to the nucleus. In the nucleus, NCID binds to the 
transcription factor CSL and drives the transcription of target genes 187. The main target gene 
of Notch signaling is Hes1 (hairy and enhancer of split 1), which in turns acts as a repressor 
of Atoh1 (atonal homolog 1, also known as Math1) 188, a crucial regulator of secretory lineage 
differentiation. As a consequence, blocking Notch signaling (for example through γ-secretase 
chemical inhibition) 144 or overexpressing Atoh1 189 results in a preponderant fate 
specification of proliferative precursors into secretory cells. Therefore, Notch signaling 
represents a central switch to regulate secretory vs. absorptive lineage commitment decision. 
Moreover, repression of Atoh1 in cells with active Notch signaling leads to downregulation 
of Dll1 expression, thus preventing the cell to produce its own Notch ligand. This 
phenomenon is called “lateral inhibition” and functions so that a central cell expressing Notch 
ligands activates Notch receptors on surrounding cells, which are in turn inhibited to produce 
their own ligand and propagate the signal 187. On the other hand, secretory progenitors 
express Dll1 and as a consequence suppress the secretory fate in surrounding cells, which 
upon Notch activation commit to the absorptive lineage 190. Hence, Notch signaling 
represents a binary switch (stochastically turned “on” and “off” based on lateral inhibition) 
driving absorptive vs. secretory fate specification and ensuring a constant ratio between 
different lineages.  
In the stem cell niche, Notch ligands are produce by Paneth cells (Dll1 and Dll4), while in the 
transit amplifying zone are expressed by secretory progenitors (Dll1). Paneth cells-derived 
Notch ligands signal on Notch-expressing CBCs driving the expression of Olfm4 and their 
proliferation and survival 191. 
3.2.3 EGF 
EGF is a growth factor important to promote survival and proliferation of intestinal stem cells 
and transit amplifying progenitors. Upon binding of EGF, the EGF receptor tyrosine kinase 
EGFR (also known as HER1 or ErbB1) homodimerize and initiate a pro-proliferative 
signaling cascade involving mitogen-activated protein kinase (MAPK), phosphatidyl-inositol 
3-kinase (PI3K), c-Jun N-terminal kinases (JNK), phospholipase C (PLC) and Jak/STAT 
pathways 192. Owing to its role as an important pro-proliferative signal, EGF levels require a 
tight control as overactivation of this pathway has been linked to neoplastic progression. To 
this aim, ISCs express the EGFR inhibitor Lrig1 mediating ubiquitination and degradation of 
EGFR. Consistent with its role as a negative feedback, genetic deletion of Lrig1 results in 
abnormal crypt expansion and enlarged intestine in mice 193.  
Ligands of EGFR (such as EGF, TGFα, Areg or Epiregulin) are produced by Paneth cells 140, 
by the mesenchyme underlying the crypt 194 and by immune cells 40. As a key niche growth 
factor, EGF is one of the crucial components used in organoids cultures 154. However, unlike 
Wnt and Notch, EGF signaling is not required to maintain stem cells identity but rather to 
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promote their activity. Indeed, removal of EGF does not cause stem cell loss but only induces 
a quiescent state in Lgr5+ cells, which is reversible upon EGF restoration 195. 
3.2.4 BMP 
Bone morphogenetic proteins, members of the TGF-β superfamily, are essential mediators of 
intestinal epithelial cells differentiation. Binding of BMPs (BMP2 and 4 in the intestine) to 
their receptors (Bmpr1 and 2) mediate the phosphorylation of SMAD1, 5 and 8, which then 
bind to SMAD4 and translocate to the nucleus to mediate target gene expression. Among the 
direct target genes of BMP signaling are DNA-binding protein inhibitor (Id) 1, 2 and 3 196. 
The main function of the BMP pathway is to counteract pro-proliferative signals in the stem 
cell niche and instead provide a pro-differentiation signal. As a consequence, deletion of 
Bmpr1 in mice results in expansion of ISCs and TA cells and formation of benign polyps 197, 
recapitulating the phenotype of patient with juvenile polyposis carrying inactivating 
mutations in the BMP pathway 198. BMPs are produced by inter-crypts and inter-villus 
mesenchymal cells 199. However, while in the villus region BMP signaling is essential to 
boost differentiation of maturing enterocytes, in the crypt region this pathway needs to be 
tightly controlled to ensure equilibrium with pro-stemness signals. To this aim, mesenchymal 
cells producing BMPs in the crypt proximity also produce BMP inhibitors, including Noggin, 
Chordin-like 1 and Gremlin1 and 2 200. This way, an increasing gradient of BMP availability 
is established moving upward along the crypt-villus axis. 
 
Figure 3. Schematic representation of a small intestinal crypt and niche signals. 
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3.3 Epithelial response to damage 
The intestinal epithelium is under the constant risk of extrinsic and intrinsic insults that 
hamper the homeostatic self-renewal and can result in overt damage. In such scenario, the 
epithelium needs to boost and exploit a regenerative program that enables repair of the 
injured barrier. Proving the regenerative capacity of the intestinal epithelium, irradiation, 
acute inflammation or surgical resection are examples of insults damaging barrier integrity 
that are followed by an hyper-proliferative response of the crypt and crypt fission (a process 
whereby two independent crypts are generated from one) 201,202. The regenerative response to 
damage is achieved through different strategies: (a) the “two-stem cell model” where rare and 
quiescent stem cell populations poorly contributing to homeostatic regeneration, are essential 
in response to damage; (b) niche signals (described above in the “Intestinal stem cell niche”) 
are enhanced over the homeostatic range, thus boosting the proliferative capacity of stem 
cells; (c) specific inflammatory cues generated in response to injury signal to ISCs and 
enhance their activity; (d) specific dietary regimens and nutritional intake modulate stem cells 
activity; (e) when ISCs are ablated by damage, committed progenitors display a plastic 
behavior and regain stem cell potential (“reverse” stem cell potential) 203. In the following 
paragraphs these strategies are briefly presented. 
3.3.1 (a) “Two-stem cell model” 
As described above, +4 reserve stem cells, owing to their quiescent nature, are less 
radiosensitive and spared from damage allowing repopulation of the stem cell pool 165,204. 
However, another study combining CBC ablation and intestinal damage reported that +4 
reserve stem cells are dispensable for tissue repair, while CBCs are essential 205. Recently, by 
single cell transcriptomic analysis of intestinal crypts undergoing irradiation-induced damage, 
a new population called “revival stem cells” has been identified. These cells, poorly 
represented during steady state, rapidly expand in response to damage and drive barrier 
regeneration 206. 
3.3.2 (b) Niche signals 
Most of the niche signals (see above), normally promoting homeostatic stem cell activity, are 
essential to mediate the regenerative response when damage occurs. For instance, deletion of 
c-Myc, a Wnt target gene, results in severe crypt loss following irradiation 207. On the other 
hand, administration of R-spondin 1 favors repair following chemotherapy 208. 
The Hippo pathway has recently emerged as key contributor to intestinal regeneration, while 
poorly contributing to homeostasis. Upon Hippo pathway activation (encompassing a 
multitude of inputs including mechanotransduction, GPCR signaling, metabolite sensing), the 
kinase MST (1 and 2) phosphorylates LAT1/2 kinases, which in turn phosphorylate and 
inactivate Yes-associated protein (YAP) and Tafazzin (TAZ) by sequestering them in the 
cytoplasm 209. In the context of chemical or radiation injury, YAP and TAZ negatively 
regulate Wnt, thus inhibiting uncontrolled stem and Paneth cells expansion upon regeneration 
and limiting the risk of microadenomas formation 210,194. Therefore, Hippo signaling ensures 
that Wnt levels are in the optimal range to allow effective regeneration while avoiding crypt 
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exhaustion. On the other hand, YAP fuels the EGF pathway by boosting Egfr signaling 194. 
Altogether, these studies suggest a role of YAP in driving regeneration by enhancing stem 
cells growth factor (i.e. EGF signaling) and by reprograming ISCs through Wnt inhibition. 
3.3.3 (c) Pro-regenerative inflammation 
Barrier damage in the intestine results in exposure to a plethora of exogenous antigens and 
pro-inflammatory mediators leading to activation of the immune system and efficient 
mounting of an inflammatory response. While on one hand the immune system ensures 
elimination of sources of extrinsic and intrinsic damage, on the other hand is actively 
involved in promoting tissue remodeling and re-establishment of homeostasis. Different 
secreted interleukins have been shown to play a pivotal role in driving intestinal stem cell 
activity. As an example, IL-22 produced by ILC3s in response to radiation-induced injury 
drives stem cells proliferation and barrier repair (see above in “ILC3” section). Similarly, 
type 2 mediators produced by ILC2s (IL-13 and Areg) boost epithelial cell proliferation and 
skewing towards secretory cells necessary to fight helminth infection (see above in “ILC2s” 
section). Recently, a novel role has been assigned to T cell responses in driving intestinal 
stem cell fate specification and self-renewal. Intestinal T cells have been postulated to interact 
with ISCs via the expression of MHC-II molecules on the latter. Sensing of pro-inflammatory 
Th cytokines (such as IL-17 or IL-13) drives ISCs differentiation and fate specification. On 
the contrary, presence of regulatory cytokines (such as IL-10 normally produced by Treg 
cells) favors ISCs self-renewal 45. Therefore, these studies display a new scenario where the 
stem cell pool is rewired by the inflammatory milieu in the surrounding microenvironment. 
3.3.4 (d) Nutrition 
Different dietary regimens can highly alter the proliferative response of intestinal stem cells. 
Starvation (acute food deprivation) and caloric restriction (long-term reduction in nutrient 
intake) are associated with decreased epithelial surface (less enterocytes and shorter villi), 
reduced cycling of TA progenitors and in parallel a direct expansion and activation of Paneth 
cells (through mTORC1) leading to expansion of the CBC pool 211. This way, in a scenario of 
limited access to nutrients our body minimizes energy expenditure (by reducing the epithelial 
surface) and builds up a stock of stem cells poised to re-establish a normal architecture as 
soon as re-feeding takes place. As a consequence of this quiescent status induced by caloric 
restriction, mice undergoing fasting are more protected against lethal DNA damage and 
display stem cells survival and barrier integrity 212.  
In contrast to starvation, exposure of mice to a high fat diet results in Paneth cell reduction. 
However, unexpectedly, this phenomenon is paralleled by expansion of the stem and 
progenitor cells pool. Mechanistically, PPARδ activation (induced by fatty acids enriched in 
high fat diet) drives expression of Jag1 and 2 and higher sensitivity to Wnt in CBCs. As a 
consequence, stem cells become independent of Paneth-derived Notch signaling (by 
producing their own ligands) and acquire the ability to survive and proliferate in the absence 
of the epithelial niche 213. Escaping from the homeostatic control of the stem cell niche, CBCs 
are exposed to the risk of uncontrolled proliferation and malignant transformation. Indeed, 
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PPARδ treated TA cells display higher tumorigenic potential, possibly explaining the link 
between obesity and colorectal cancer 214. 
Besides fatty acids (signaling through PPARδ), another link explaining risk of tumor 
formation in the context of obesity is cholesterol (also enriched in high fat diet). Feeding mice 
with high cholesterol diet enhances stem cells proliferation and boosting cholesterol 
biosynthesis results in increase tumor formation in the ApcMin/+ mouse model 215. However, 
our body has a system in place to avoid toxic overload of cellular cholesterol, which relies on 
cholesterol metabolism into oxidized derivatives called oxysterols (see below in “cholesterol 
metabolism”). The role of cholesterol metabolism in the context of intestinal regeneration and 
tumorigenesis remains poorly addressed. In the last manuscript included in this thesis, we 
have shown how cholesterol metabolism is an adapted tissue response to damage which leads 
to enhanced intestinal regeneration while limiting the risk of tumor development. 
3.3.5 (e) Plasticity of committed progenitors 
Many of the damage models used to study regeneration are characterized by almost complete 
ablation of the stem cell pool at the crypt bottom (as seen in irradiation, chemotherapy or 
diphtheria toxin mediated stem cells elimination). However, the epithelium recovers in few 
days and new functional crypts with new CBCs are formed. This finding implies that in a 
process independent of self-renewal, CBCs can be generated from other cells surviving the 
damage. Besides the +4 reserve stem cells, several other committed progenitors (including 
secretory precursors 190,216, Paneth cells 217 and enterocytes precursors 218) have been shown 
to de-differentiate, migrate to the crypt bottom and repopulate the stem cell pool, giving rise 
to all the differentiated enterocytes. 
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4 CHOLESTEROL METABOLISM 
Cholesterol is a crucial building block of the cell membrane and it plays an integral part in 
allowing transmembrane receptor signaling via the formation of lipid rafts. Moreover, 
cholesterol serves as the substrate for the generation of several metabolites, such as steroid 
hormones, bile acid and oxysterols. Despite these homeostatic roles, a tight control of its 
levels is required as excessive cholesterol is toxic and associated to development of several 
chronic metabolic disorders, such as diabetes and atherosclerosis 219. One way to keep 
cholesterol levels in check is an intrinsic negative feedback mechanism. High cellular 
cholesterol levels result in the direct inhibition of sterol regulatory element-binding protein 
(SREBP) transcription factors, which promote cholesterol biosynthesis 220. On the other hand, 
metabolic generation of oxysterols represents a second strategy to avoid cholesterol overload. 
According to the “oxysterol hypothesis”, some oxysterols have been shown to directly inhibit 
SREBP activity and to promote reverse cholesterol transport by binding to their receptor 
Liver X Receptor (LXR) 221,222. Reverse cholesterol transport is a process that mediates 
removal of cholesterol from peripheral tissues, transport to the liver and excretion in the form 
of bile acid 223,224. Besides this purely metabolic activity, oxysterols have been shown to be 
critical in controlling several biological processes including cell proliferation, migration and 
immune cells function both via regulation of cellular cholesterol load and through other 
pathways 225. In the following paragraphs, an overview of the most characterized oxysterols 
and the function of the main oxysterol receptors is presented. 
4.1 Oxysterols 
Oxysterols are hydroxylated derivatives of cholesterol generated via either enzymatic or non-
enzymatic conversion 226. Non-enzymatic oxysterols can originate from the diet or they are 
produced endogenously by free radical attack of cholesterol. Enzymatically produced 
oxysterols instead are generated via the activity of specific enzymes (mainly belonging to the 
cytochrome P450 family). This class of oxysterols comprises intermediates of the bile acid 
synthesis and steroid hormones as well as oxysterols selectively generated in specific cell 
types 226. Below a brief description of the biosynthesis and function of the main oxysterols is 
provided. 
4.1.1 27-hydroxycholesterol 
27-hydroxycholesterol (27HC) is generated via the enzymatic conversion of cholesterol 
mediated by the sterol 27-hydroxylase (Cyp27a1), a mitochondrial cytochrome P450 oxidase. 
Under homeostatic condition, 27HC is the most abundant oxysterol found in circulation 227. 
27HC is a substrate for bile acid generation and Cyp27a1 is involved both in the classic and 
in the alternative pathway of bile acid production 227. As a result, mice deficient in Cyp27a1 
display severe defects in bile acid synthesis 228. Moreover, in line with the “oxysterol 
hypothesis”, 27HC has been shown to inhibit the activity of SREBP and thus limit cholesterol 
biosynthesis. Besides these metabolic roles, 27HC can bind to two nuclear receptors: the 
estrogen receptor (ER) and LXR. Binding of 27HC to ER has been linked to a pro-
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inflammatory response in MΦ in the context of atherosclerosis 229 and to a pro-metastatic role 
in breast cancer 230. Contrary to these pro-inflammatory functions when binding to ER, 
binding of 27HC to LXR seems to be mainly associated to an anti-inflammatory effect (see 
below in “Liver X Receptor”) 225. Whether inflammation can induce Cyp27a1 expression and 
generation of 27HC as a negative feedback mechanism remains unknown. So far a role in 
inducing Cyp27a1 expression has been attributed to RA 231, the steroid- and bile acid-
activated pregnane X receptor (PXR) 232 and LXR 233. In our study, we have shown that 
intestinal barrier damage induces upregulation of Cyp27a1 and that this process contributes to 
intestinal regeneration. 
4.1.2 25-hydroxychlesterol 
25-hydroxycholesterol (25HC) is generated via the activity of the cholesterol 25-hydroxylase 
(Ch25h). 25HC can inhibit SREBP activity, bind to LXR (although with a lesser affinity 
compared to 27HC) 234 and function as an inverse agonist of RORα (26812621), a nuclear 
receptor involved in circadian rhythm regulation and ILC2 development. Induction of Ch25h 
is observed in the context of viral infection and appears to be mediated by type I interferon 
(IFN-I), especially in myeloid cells 235. In line with this, 25HC has been attributed an antiviral 
effect by inhibiting viral particle fusion to the cell membrane 236 and by inhibiting cholesterol 
biosynthesis 237. In parallel to its anti-viral function, 25HC play an important anti-
inflammatory role. Cyster’s lab elegantly demonstrated that Ch25h expression dampens 
production of pro-inflammatory cytokine such as IL-17 from αβ and γδ T cells 238 and IL-1β 
from MΦs by inhibiting inflammasome activation in response to LPS stimulation 239. 
Interestingly, together with IFN-I, endotoxin administration stimulates Ch25h expression and 
25HC production 240. Therefore, production of this oxysterol might represent an adapted 
response to inflammation directed at dampening it. 
25HC can be further processed to generate 7α,25-dihydroxycholesterol (7α,25-HC) via the 
activity of the Cytochrome P450 Family 7 Subfamily B Member 1 (Cyp7b1) enzyme. 
Expression of this oxysterol is predominant in immune cells where it plays key biological 
functions by acting on the receptor EBI2 (see below in “EBI2 receptor”). 
4.1.3 24-hydroxycholesterol 
24-hydroxycholesterol (24HC) is produced via the activity of the cytochrome P450 enzyme 
cholesterol 24-hydroxylase (Cyp46a1). 24HC is considered a brain specific oxysterol (known 
as cerebrosterol), with a pattern of expression almost exclusively restricted to neurons 241. By 
acting on the receptor LXR, 24HC mediates elimination of excess brain cholesterol 242. 
Unlike 24HC, which is produced in loco, 27HC is also found in the brain tissue, but in this 
case coming from the circulation and crossing the blood brain barrier. Remarkably, altered 
levels of 24HC and 27HC have been reported in several neurodegenerative disorders 
including multiple sclerosis 243, Alzheimer disease 244 and Parkinson’s disease 245. In 
particular, patients with long history of multiple sclerosis (relapsing-remitting and primary 
progressive patients) have lower plasma concentration of 24HC compared to early-diagnosed 
 34 
patients 243. These results imply a role for oxysterols in the modulation of neuroinflammation 
and point towards the anti-inflammatory role of LXR (see below in “Liver X Receptor”). 
4.2 EBI2 receptor 
EBI2 is a G protein-coupled receptor that binds to 7α,25-HC. It is expressed on different 
immune cells (including B cells, T cells, DCs and ILCs) where it plays a critical role in 
controlling cell migration. 
B cells display the highest EBI2 expression among all immune cells and B cell receptor 
(BCR) stimulation further upregulates it. Activation of EBI2 on B cells drives their migration 
towards appropriate intra- and extra-follicular regions following antigen recognition, which 
enables a functional antibody response 246,247. B cells deficient for EBI2 or disruption of the 
enzymatic machinery required for the production of EBI2 ligands results in a microanatomic 
disorganization of B cells coupled with a reduced T cell-dependent antibody response 248,249. 
EBI2 ligands are mainly produced by lymphoid tissue stromal cells enriched in the outer 
follicle and in interfollicular regions 250. This expression pattern, defined based on the spatial 
analysis of Ch25h expressing stromal cells, creates a micro-gradient of EBI2 ligands that 
control B cell migration in lymphoid organs. How Ch25h induction is governed among 
different stromal subsets in different area of lymphoid tissue remains unexplored.  
Similar to B cells, EBI2 expression on DCs drives their chemotaxis. Splenic CD4+ DCs, via 
EBI2 activation, expand and localize in the marginal zone bridging channels where they can 
pick up blood-borne antigens. This process subsequently favors antigen presentation to T 
cells and generation of a T cell-dependent antibody response 251.  
Finally, follicular T cells are guided towards the interface of the B cell follicle and the T cells 
zone via sensing of 7α,25-HC by EBI2 receptor 252. 
Recently, we and others have shown that EBI2 expression on ILC3s is required for their 
positioning in cryptopatches, thus driving formation of isolated lymphoid follicles 253 and 
immunity to enteric bacterial infection 104. 
4.3 Liver X Receptor 
LXR is a sterol activated transcription factor belonging to the class of nuclear receptors. Two 
isoforms of LXR are present, LXRα (Nr1h3) and LXRβ (Nr1h2), which bind to the same 
ligands and regulate the same target genes expression but differ in tissue distribution. While 
LXRα is mainly expressed in metabolically active tissues and cells types (such as liver, 
intestine, adipose tissue and macrophages), LXRβ is ubiquitously expressed 219. As described 
above, the main ligands activating LXR are oxysterols (predominantly 27HC and 24HC), but 
also intermediates of the cholesterol biosynthetic pathway, such as desmosterol 254. To 
function as a transcription factor, LXR heterodimerizes with retinoid X receptors (RXRs) 255. 
When activating ligands are absent, LXR-RXR heterodimer is bound to its response element 
on the DNA, in complex with co-repressor and thus inhibiting the transcription of target 
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genes 256. Upon ligand binding, co-repressors are released and co-activators recruited leading 
to target gene activation. The main target genes of LXR encode for proteins involved in 
reverse cholesterol transport, such as the membrane transporters Abca1 and Abcg1 mediating 
cellular cholesterol efflux 257. Besides directly regulating the transcription of target genes, 
LXR can negatively regulate gene expression by inhibiting the activity of other transcription 
factors, such as NF-κB or AP-1, two important pro-inflammatory genes 223,258. 
Together with regulating cholesterol homeostasis, LXR plays an important immunological 
role by suppressing inflammatory responses. In line with this hypothesis, the use of LXR 
synthetic ligands has been proposed to dampen the progression of various inflammatory 
diseases in mice, including atherosclerosis, Parkinson’s diseases or experimental autoimmune 
encephalomyelitis (EAE, a mouse model for multiple sclerosis)219,225. Interestingly, loss of 
LXR in mice results in increased susceptibility to chemically induced colitis259, but whether 
regulation of oxysterol levels in the intestine has been adapted as a measure to control 
inflammation remains unaddressed.  
The immune-regulatory role of LXR has been extensively characterized in MΦ. The use of 
LXR agonist in vitro on LPS-stimulated MΦs inhibits the expression of pro-inflammatory 
mediators, including cyclooxygenase 2, inducible nitric oxide synthase, IL-6 and IL-1β223,260. 
In vivo, phagocytosis of apoptotic neutrophils raises cholesterol levels in MΦs and, through 
LXR activation, inhibits the production of IL-23, IL-17 and G-CSF 261. In addition, LXR 
activity has been associated with MΦ survival and antimicrobial activity in the context of 
bacterial infections, such as Listeria monocytogenes262, Escherichia coli and Salmonella 
typhimurium263. 
Besides regulating myeloid cells, recent studies propose a role for LXR in regulating 
lymphocyte biology. Upon T cell activation, induction of sulfotransferase family 2B member 
1 (SULT2B1, an enzyme promoting oxysterol sulfation and inactivation) results in decreased 
LXR activity with consequent cholesterol accumulation required for new membrane 
formation and proliferation264. In line with these results, mice lacking LXR undergo 
lymphoid hyperplasia and develop autoimmune glomerulonephritis and lupus-like disorders 
with age264,265. In addition, LXR activation participates in T cell differentiation by inhibiting 
AhR-mediated Th17 induction. As a consequence, loss of LXR is associated with greater 
severity of EAE, possibly by enhancing the pathogenic effect of Th17266. Recently, an 
indirect control of adaptive immunity has been attributed to LXR, involving regulation of 
DCs functioning as an orchestrator of T and B cell response. In detail, by modulating cellular 
cholesterol load in DCs, LXR enhances T cell priming and the production of B cell trophic 
factors, thus coupling cholesterol metabolism to DC-driven T and B cell proliferation267. 
Furthermore, LXR functions as a regulator of DC biology by inhibiting their migration to 
lymph nodes and, as a consequence, antigen-presentation. Upon cancer development, tumor 
cells produce oxysterols, which cause LXR-mediated down-regulation of CCR7 on DCs and 
tumor immune escape268. Overall, oxysterol sensing and LXR activity are important 
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contributors to immune regulation and control of inflammation. However, their role in 
intestinal homeostasis remains poorly understood. 
Besides modulating immune cell functions, LXR plays crucial anti-proliferative roles in 
epithelial cells. By overexpressing LXRα in intestinal epithelial cells, Lo Sasso and 
colleagues showed that genetic (ApcMin/+) and chemically induced (AOM-DSS) intestinal 
tumor formation was inhibited 284. This study suggests that by decreasing the cellular 
cholesterol pool size, LXRα restrains the proliferative potential of intestinal tumor cells and 
induces caspase-dependent apoptosis. In the last manuscript included in this thesis we have 
added on these data and showed that while LXR activation restrains intestinal tumorigenesis, 
at the same time it promotes epithelial cell regeneration in the context of acute intestinal 
injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  37 
5 AIMS OF THE THESIS 
 
The overall aim of this thesis was to investigate how ILC and epithelial cell biology was 
modulated in the context of intestinal homeostasis, inflammation and tissue response to 
damage. In particular, the three specific aims were as follows: 
 
Study I: To investigate the ability of ILC progenitors in the bone marrow to respond to 
peripheral inflammation. 
 
Study II: To functionally characterize how cholesterol metabolism modulates intestinal ILC 
functions. 
 
Study III: To explore the physiological tissue response to damage and how cholesterol 
metabolism controls the regenerative potential of the intestinal epithelium. 
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6 MATERIALS AND METHODS 
This chapter briefly summarizes the main materials and methods utilized in the three 
manuscripts included in this thesis. For a more detailed description, please refer to the 
“materials and methods” section of each manuscript. 
6.1 Mouse studies (Study I-II-III) 
All experiments were approved by the Stockholm Regional Ethics Committee and the 
responsible federal health authorities of the State of Hamburg. Mice were maintained under 
specific pathogen free conditions and both male and female mice were used between 6-20 
weeks of age. All experiments were performed in accordance with national and institutional 
guidelines and regulations. 
6.2 Processing of tissues (Study I-II-III) 
Single cell suspension from spleen, lymph nodes and liver was obtained through smashing on 
70µm cell strainers. Liver leukocytes were then enriched through Percoll gradient (Sigma 
Aldrich). Lung tissue was minced with scissors and digested with 0.15 mg/ml Liberase TL 
and 0.1 mg/ml DNase I (Roche) followed by Percoll gradient. Bones were crushed with a 
pestle and filtered through 70µm cell strainers. Intestinal tissue (both small intestine and 
colon) were first incubated with HBSS containing 10% FCS, 5 mM EDTA, 1 mM DTT and 
15 mM HEPES to remove epithelial cells, followed by digestion with serum-free HBSS 
containing liberase TL (0.15 mg/ml) and 0.1 mg/ml DNase I and Percoll gradient. For 
intestinal crypts isolation, small intestine was incubated in 10mM EDTA on ice followed by 
filtration through 70µm cell strainer. 
6.3 Flow cytometry and fluorescent activated cell sorting (Study I-II-III) 
Samples were first stained with live/dead fixable viability dyes (eBioscience) and blocked 
with Fc-blocking (CD16/32) antibody (eBioscience). Samples were then stained at 4°C with 
panels of fluorescently labeled antibodies for surface antigens. For intracellular staining, cells 
were fixed and permeabilized using the fixation and permeabilization buffers (from the 
Foxp3 staining kit, eBioscience) followed by staining at RT with fluorescently labeled 
antibodies specific for intracellular proteins. For flow cytometry analysis, samples were 
acquired using FACS Canto II or FACS LSR Fortessa flow cytometers (BD Biosciences) and 
analyzed with FlowJo software (TreeStar). For fluorescent activated cell sorting, samples 
were sorted using a BD FACSAriaI or AriaIII (BD Biosciences). In case of sorting of rare 
populations (such as CHILPs in Paper I), a pre-enrichment with depletion of lineage+ cells 
through magnetic beads (Miltenyi Biotec) was performed. 
6.4 Intestinal injury models (Study I-II-III) 
Several intestinal injury models were used in the three manuscripts included in this thesis. 
Dextran sulfate sodium (DSS) induced colitis (I-III) was induced by feeding mice with 2-3% 
(w/v) DSS (MP Biomedicals or TdB Consultancy) dissolved in drinking water ad libitum for 
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5-7 days, followed by regular water administration to allow tissue repair. Alternatively (II), 
colitis was induced by injecting 100µg of CD40 (FGK45) antibody intraperitoneally in Rag1-
deficient mice.  
Small and large intestinal damage (III) was induced by exposing mice to a dose of 10Gy 
from an X Radiation Unit.  
Chemically induced colon tumor (III) was induced by i.p. injection of azoxymethane (AOM, 
Sigma Aldrich) followed by three cycles of DSS administration in drinking water, alternated 
with two weeks of regular water. 
6.5 Organoid culture (Study III) 
Following isolation, small intestinal crypts were resuspended in 30%-70% ratio of 
DMEM/F12 and Matrigel (Corning) and plated in pre-warmed 48 well plates. Complete ENR 
medium including 500µg/ml of EGF (R&D), 250-500ng/ml of recombinant murine R-
Spondin (R&D) and 100ng/ml of Noggin (Peprotech) was overlaid. Complete fresh medium 
was changed every other day and crypt domain quantification was usually performed at day 3 
of culture, followed by harvesting for RNA extraction at day 4-7 of culture. 
6.6 Quantitative PCR analysis (Study I-II-III) 
Tissue collected for RNA extraction was stored in RNALater (Invitrogen) followed by bead-
beating lysis (Precellys) in RLT buffer (Qiagen) + 2% β-mercaptoethanol. Cells collected for 
RNA extraction were resuspended in RLT buffer (Qiagen) + 2% β-mercaptoethanol. RNA 
extraction was performed using RNeasy Mini Kit (Qiagen) according to manufacturer’s 
instructions. Alternatively, cells were resuspended in TRIzol reagent (Invitrogen) and RNA 
was extracted by chloroform phase separation. Reverse transcription to cDNA was performed 
using iScript RT Supermix (Biorad) (I-II-III), SuperScript First-Strand Synthesis System 
(Invitrogen) (II) or High-capacity cDNA Reverse Transcriptase Kit (applied Biosystems) 
(II). Gene expression analysis was performed by quantitative real time PCR using either iTaq 
Universal SYBR Green Supermix (Biorad) or Taqman probes (Thermo Fisher Scientific). 
6.7 Statistical analysis (Study I-II-III) 
Unpaired two-tailed Student’s t-test with 95% confidence interval was used when comparing 
two independent groups. When the same biological sample was tested with different 
biological stimuli, paired t-test was used. When comparing more than two groups (unless 
specifically indicated), data were analyzed using one-way ANOVA with Bonferroni’s 
multiple comparisons test. Data were analyzed using GraphPad Prism Software 6.0e. 
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7 RESULTS AND DISCUSSION 
This section provides a brief summary of the main findings of each study and discusses their 
relevance. More details can be found in the manuscripts attached to this thesis. 
7.1 Flt3 ligand promotes expansion of ILC precursors (Study I) 
Development of ILCs mainly takes place during the fetal and post-natal window. 
Subsequently, peripheral ILCs display a tissue resident behavior and do not seem to rely on 
circulating progenitors for their renewal under homeostatic conditions 133. Nevertheless, the 
adult murine bone marrow (BM) harbors a population of ILC progenitors endowed with the 
ability to generate all different mature ILC subsets. A plausible explanation to reconcile this 
paradox is that BM ILC precursors represent a backup poised to give rise to new ILCs in order 
to replenish the exhausted mature peripheral pool when inflammation occurs. In line with this 
hypothesis, at a later time point after infection, peripheral ILCs partially lose their ability to 
expand locally and start to depend on replenishment from hematogenous sources 133. We, 
therefore, tested whether ILC precursors in the BM are capable of sensing peripheral 
inflammation and react with a demanded ILC-poiesis, similar to what has been shown for 
myeloid progenitors in the context of “emergency myelopoiesis” in response to systemic 
infections.  
Flt3L is a hematopoietic cytokine that promotes proliferation of myeloid and lymphoid 
progenitors under homeostatic conditions (including DCs, NK and common lymphoid 
progenitor cells) 269,270. In the context of inflammation (such as malaria, cytomegalovirus 
infection or rheumatoid arthritis) 271,272, Flt3L levels increase and influence hematopoiesis, 
hence representing a good candidate to test our hypothesis. 
We first tested whether increased levels of Flt3L were affecting the pool of ILC precursors in 
the BM. To this aim, we injected mice with a B16 melanoma cell line constitutively secreting 
Flt3L (B16-Flt3L), a tool that allowed us to achieve continuous systemic production of this 
cytokine within two weeks. By comparing the BM of mice B16-Flt3L-injected with mice 
injected with B16 only, we observed a drastic expansion of CHILPs (common helper ILC 
precursors) 30 and of ILCP (ILC precursors that lost the ability to generate LTi) without 
affecting the pool of committed ILC2 progenitors (ILC2P) (Figure 4).  
 
Figure 4. Expansion of CHILPs in response to B16-Flt3L. 
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Interestingly, CHILPs are defined, among other markers, by the absence of Flt3 receptor 
expression. On the contrary, upstream of CHILPs, CLPs express Flt3 receptor. Whether Flt3L 
signaling in CLP skews their differentiation towards the ILC lineage is an intriguing hypothesis 
that remains to be tested.  
Given the observed expansion of ILC precursors in the BM, we tested whether increased Flt3L 
levels affected the peripheral pool of mature ILCs. To our surprise, we did not detect any 
difference in frequencies and numbers of peripheral ILC1, ILC2 and ILC3s in small intestine, 
colon, lungs and liver upon B16-Flt3L injection. This finding might be explained by the short-
term exposure to high Flt3L levels (two weeks), which might not be enough to affect the pool 
of CHILPs, generate new ILCs and expand the pool of mature ILCs in the tissues. In line with 
this hypothesis, a long-term modification of Flt3L levels or Flt3L sensing (by using mice 
deficient for Flt3 receptor or transgenic for Flt3L) results in expansion of peripheral ILCs 273. 
Alternatively, in our system, expansion of mature ILCs does not occur due to lack of peripheral 
inflammation, which might create an empty and more accessible niche in the tissue for BM-
generated ILC replenishment. 
To confirm that the expanded pool of CHILPs in the BM were selectively committed to ILCs 
and to test whether their differentiation potential was altered by Flt3L exposure, we exploited 
an in vivo adoptive transfer approach. Sorted CHILPs from control and B16-Flt3L injected 
mice were injected into lymphopenic Rag-/-Il2rg-/- mice. Analysis of recipient mice confirmed 
that CHILPs were selectively giving rise to all helper ILCs in vivo and that Flt3L-mediated 
expansion was not affecting their ability to differentiate uniquely into ILCs (Figure5).  
 
Figure 5. Flt3L-expanded CHILPs give rise selectively to ILCs. 
Our data alluded to a role of Flt3L in regulating the size of ILC precursors in the BM. With our 
initial hypothesis in mind, we tested whether this axis occurs upon inflammatory insults, where 
Flt3L is not artificially modulated (as in our initial model with B16-Flt3L injection). We first 
tested if Flt3L systemic levels were modulated upon intestinal inflammation and whether this 
phenomenon was accompanied by expansion of ILC precursors in the BM. We reasoned that 
ILC precursors might expand in a colitis model since expansion of mature ILCs has been 
observed in the inflamed colon of inflammatory bowel disease (IBD) patients 33,274 and in 
mouse models of chronic intestinal inflammation 275. However, both in the serum of mice 
exposed to chemically induced colitis and in the plasma of IBD patients, we did not observe 
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alteration in the Flt3L levels when compared to their respective controls. Similarly, CHILPs 
numbers were unaffected in the BM of mice undergoing colitis.  
On the other hand, in line with previous reports, we observed altered Flt3L levels in circulation 
when analyzing another inflammatory setting, namely malaria. Both in plasmodium infected 
mice and in human malaria patients we detected increased Flt3L in serum and plasma 
respectively. Interestingly, increased systemic levels of Flt3L were kinetically preceding 
expansion of CHILPs in the BM of infected mice.  
Altogether, these data propose a new role for Flt3L in controlling the size of ILC progenitors in 
the BM. Moreover, we propose a potential involvement of the Flt3L-CHILP axis in the context 
of specific inflammatory settings (for example malaria). The functional consequences of 
inflammation-mediated ILC precursors expansion still remain to be addressed. Analysis of 
ILCs in inflamed tissues, especially in the context of chronic inflammation with enhanced 
Flt3L levels, or pharmacologic/genetic blocking of this axis during inflammation might 
represent a future outlook to reveal a novel biological function of “inflammatory ILC-poiesis”. 
7.2 Oxysterol sensing through EBI2 controls ILC3 function (Study II) 
In the second manuscript included in this thesis, we investigated the function and migratory 
potential of ILCs in the periphery. As immune sentinels and gatekeepers of tissue homeostasis, 
ILCs are endowed with the ability to sense and respond to cues and various metabolites from 
the local environment 36,276. However, whether ILC function is modulated by cholesterol 
metabolism remains unaddressed. In this study, in collaboration with Tim Willinger’s group, 
we described a novel role for the GPCR Epstein Barr virus-induced gene 2 (EBI2) sensing 
cholesterol metabolites and driving ILC3 migration, lymphoid tissue formation and 
inflammation in the colon. 
EBI2 (also known as GPR183) is a receptor for hydroxylated derivatives of cholesterol, named 
oxysterols (in particular 7α,25-dihydroxycholesterol, 7α,25-HC), regulating chemotaxis of B 
cells, T follicular helper cells and DCs 277. However, whether EBI2 can control ILC function 
remains unknown. To address this question we made use of reporter mice for EBI2 (GPR183-
GFP mice), in vitro migration assay and mice deficient in Gpr183 or the enzyme necessary to 
produce EBI2 ligands (i.e. Ch25h). We showed that adult LTi-like ILC3s express EBI2 and 
migrate towards 7α,25-HC in vitro. In vivo, expression of EBI2 intrinsically on ILC3 was 
necessary to drive their migration to colonic cryptopatches and thus the formation of isolated 
lymphoid follicles (ILFs). Moreover, this phenomenon was dependent on the presence of the 
ligand, as mice lacking Ch25h phenocopied mice deficient in Gpr183 on ILC3s and displayed 
severe impairment in the formation of colonic cryptopatches. Looking for the source of 7α,25-
HC in the tissue, we observed that stromal cells defined by the expression of podoplanin, 
CD34 and CXCL13 located in cryptopatches and ILFs were the predominant cell types 
expressing the oxysterol-producing enzymes Ch25h and Cyp7b1 in a microbiota-independent 
manner. 
We then hypothesized that blocking the migration of ILC3s to colonic lymphoid tissues might 
cause defects in their function. Interestingly, ILC3s from mice lacking EBI2 produced 
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significantly lower IL-22 compared to EBI2 sufficient mice. This phenomenon was not directly 
mediated by 7α,25-HC sensing, as purified ILC3s cultured in vitro with this oxysterol did not 
show any impairment in IL-22 production. Conversely, altered ILC3 function seems to be 
secondary to the migration defect and the reduction in colonic cryptopatches formation.  
Expanding these observations beyond physiology, we observed that innate-immune mediated 
colonic inflammation (i.e. anti CD40) resulted in upregulation of the enzymatic machinery 
producing 7α,25-HC and concomitant downregulation of oxysterol degrading enzymes 
(Hsd3b7). The increased oxysterol production led to an EBI2-dependent accumulation of 
ILC3s in inflammatory foci and to an overall increase of colonic inflammation. 
Overall this study uncovered a novel mechanism of metabolite sensing by ILCs, which is 
fundamental towards the ontogenesis of lymphoid tissues in the colon. Moreover, it depicts a 
non-sessile behavior of ILC3s in the tissue, with oxysterols as cues driving functional 
positioning within cryptopatches. While EBI2 engagement on ILC3s promotes inflammation in 
the context of colitis, another oxysterol receptor liver X receptor, known to exert anti-
inflammatory functions, is also expressed by ILCs. Hence, an appealing area for future 
research will be to understand how different oxysterol signals are distributed in the intestine 
and how ILCs decode them to modulate their functions. 
7.3 Damage-induced LXR activation drives intestinal regeneration and limits 
tumorigenesis (Study III) 
In the last manuscript included in this thesis we shifted the focus towards the intestinal 
epithelium, the first cellular line of defense against environmental stressors. When intestinal 
damage occurs, a regenerative process emanating from proliferating intestinal stem cells (ISCs) 
at the bottom of the crypts ensures tissue repair and re-establishment of homeostasis. If 
regeneration fails to occur, the risk of developing chronic inflammatory disorders (such as IBD 
or leaky gut syndrome) increases, thus highlighting the importance of finding therapeutic 
strategies to boost intestinal regeneration 82,278.  
With the aim of finding pathways involved in intestinal regeneration in the context of injury, 
we adopted an unbiased approach analyzing transcriptomic datasets of intestinal tissue 
undergoing chemically induced colitis (i.e. dextran sodium sulfate-induced colitis, DSS) or 
irradiation-induced injury. During the process of tissue repair, we observed upregulation of 
pathways involved in cholesterol metabolism, characterized by the expression of target genes 
of the transcription factor liver X receptor (LXR). Therefore, we aimed at understanding 
whether LXR contributes to intestinal regeneration and if it functions as a central hub 
regulating transcription of genes involved in tissue repair.  
To study if LXR favors intestinal regeneration, we fed mice with a modified diet containing the 
synthetic LXR agonist GW3965 and we exposed them to different intestinal injury models 
(including DSS colitis and irradiation). Remarkably, we observed that activating LXR in vivo 
in the context of damage promoted tissue repair by boosting crypt cells proliferation and 
regenerative potential. We therefore decided to investigate the cell type in which LXR 
activation was necessary to promote intestinal regeneration. While we did not observe any 
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specific alteration of intestinal immune cell composition when activating LXR in vivo, mice 
specifically lacking LXR in 
intestinal epithelial cells 
displayed reduced regeneration 
upon irradiation. Further 
proving the role of LXR in the 
epithelium, intestinal crypts 
plated in vitro in the presence of 
LXR agonist generated bigger 
organoids with more newly 
formed crypt domains and 
enhanced expression of stem 
cell markers (Figure 6).  
Figure 6. LXR activation stimulates organoids growth. 
 
Our data thus far propose a novel role for LXR as necessary and sufficient in epithelial cells to 
drive intestinal regeneration. The crosstalk between ISCs and epithelial niche cells (Paneth 
cells, PC) residing in intestinal crypts is essential to promote ISC proliferation and 
differentiation and thus orchestrate barrier repair. With the aim of unraveling a cellular and 
molecular mechanism behind this pathway, we first tested in which epithelial cell type LXR 
activity was required to foster regeneration. By co-culturing wild type ISCs with either wild 
type or LXR-deficient PC, we observed that LXR expression in PC was indispensable to favor 
organoids growth in vitro. Accordingly, we measured higher expression of stem cell niche 
signals, such as Wnt3 and amphiregulin (Areg), upon GW3965 stimulation, suggesting that 
LXR activation in the stem cell niche favors intestinal regeneration. Nevertheless, we cannot 
exclude that LXR activity in stem cells is similarly required to drive their proliferation and 
differentiation. Future work exploiting mice deficient in LXR selectively in ISCs will thus be 
required to answer this question. 
Since most of the known downstream effects of LXR are regulated by its activity as a 
transcription factor, we tested which genes were specifically modulated by LXR activation in 
the intestinal crypt with the aim of finding molecular targets driving regeneration. Towards 
this, we performed a transcriptomic analysis of small intestinal crypts exposed to GW3965 for 
6 hours in vitro. Together with the known LXR target genes (such as the cholesterol pumps 
Abca1 and Abcg1), we found several other genes selectively upregulated in the context of LXR 
activation. Among these, the fatty acid-regulated transcription factor peroxisome proliferator 
activated receptor alpha (Ppara) and the E3 ubiquitin ligase ring finger protein 186 (Rnf186) 
were validated by qPCR both in vitro (organoids culture with GW3965) and in vivo (irradiated 
small intestinal crypts of mice fed with GW3965 or control diet). Interestingly, Rnf186 gene 
has been mapped in an ulcerative colitis (UC)-susceptible locus by a genome wide association 
study 279 and mice deficient in Rnf186 display enhanced sensitivity to colitis induced by DSS 
administration 280. Current investigation in the lab is aiming at understanding whether the 
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LXR-mediated pro-regenerative effect is molecularly driven by RNF186 activation or via 
PPARα, another recently described player of intestinal regeneration 179. 
Our observations propose that pharmacological LXR activation might represent a therapeutic 
strategy to boost intestinal regeneration. Accordingly, our initial unbiased characterization of 
tissue repair suggested that this pathway is physiologically upregulated in the tissue 
undergoing regeneration. On this basis, we investigated what signal was driving LXR 
activation in response to intestinal damage. Ligands of LXR are specific oxysterols (mainly 
24HC and 27HC) generated by the activity of the enzymes Cyp46a1 and Cyp27a1 
respectively. When analyzing the sections of intestinal tissues exposed to DSS- or irradiation-
induced damage we observed upregulation of Cyp27a1 coinciding with the regenerative phase. 
These data suggest that modulation of the cholesterol metabolic machinery generating the LXR 
ligand 27HC represents an adapted response to intestinal tissue damage. Probing whether 
generation of this LXR ligand was involved in barrier repair, we tested the regenerative 
potential of mice lacking Cyp27a1 enzyme. In line with our hypothesis proposing a pro-
regenerative effect of the oxysterol-LXR axis, mice lacking the enzyme generating LXR 
ligands displayed delayed recovery and impaired epithelial cells proliferation.  
Altogether, our results uncovered a novel pathway of intestinal regeneration, which might 
represent a promising target to improve the outcome of diseases associated with altered barrier 
integrity (such as IBD or graft versus host diseases). However, boosting regeneration has long 
been associated with enhanced risk of promoting malignant transformation and cancer 
progression 281. This unwanted side effect is molecularly explained by misappropriation by 
cancer stem cells of homeostatic pro-proliferative and self-renewing signals characteristic of 
ISCs. Therefore, we wanted to understand if the pro-regenerative effect of LXR activation was 
at the risk of fueling tumorigenesis. 
Towards this, we activated LXR pathway 
in vivo (by feeding mice with GW3965 
containing diet) and we tested tumor 
formation using two different models: an 
inflammation-induced colon tumor model 
(AOM-DSS) and a genetically driven 
tumor model affecting the small intestine 
(ApcMin/+). To our surprise, in both 
models, LXR activation led to a reduction 
in tumor size and numbers (Figure 7). 
 
 
 
Figure 7. LXR activation in vivo dampens tumorigenesis. 
 
This finding indicates that LXR activity in the epithelium reciprocally regulates regeneration 
and tumorigenesis. Supporting this notion, tumor biopsies of mice treated with LXR agonist 
were no longer characterized by upregulation of pro-proliferative signals, such as Wnt3 and 
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Areg as observed during regeneration, instead displayed upregulation of pro-differentiating 
(Id2) and pro-apoptotic (Atm and p27) signatures. To gain mechanistic insights, we observed 
that expression of the LXR target gene Ppara was enhanced by GW3965 administration also in 
the tumor context. Remarkably, studies in Ppara deficient animals showed increased 
susceptibility to colorectal tumors explained by reduced expression of the tumor suppressor 
gene p27 282. Thus, PPARα might represent the molecular mediator of LXR-dependent anti-
tumor effect and future experiment will be needed to prove this hypothesis.  
Overall, we uncovered an unprecedented role of LXR in driving intestinal regeneration, thus 
revealing a promising therapeutic target to boost tissue repair in the context of chronic 
inflammatory pathologies marked by aberrant mucosal healing. Further, we showed that, 
unlike most of the pro-regenerative strategies studied thus far, LXR activation is not associated 
with enhanced risk of cancer formation. Therefore, understanding how LXR uncouples 
regeneration and tumorigenesis represents an appealing future outlook for the development of 
promising and safer therapies. 
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